Heal Mesothelioma

Xarelto Lawsuit News – 2/24/2012: If you were prescribed Xarelto and have suffered negative side effects, please contact us today so that we can put you in touch with an attorney to advise you of your legal rights.

Xarelto Lawsuit: Blood coagulation is regulated by the sequential activation of vi­tamin K-dependent coagulation proteases within the intrinsic and extrinsic pathways. This involves a complex series of reac­tions that occur as a cascade and culminates in the generation of thrombin to convert soluble fibrinogen into insoluble fibrin. Maintenance of hemostasis relies on the regulated interaction of the vitamin K-dependent proteases, protease cofactors, mem­brane surfaces and receptors, calcium ions, and protease in­hibitors. Three central and fundamental enzyme complexes in the coagulation cascade are the factor Xa (FXa)-generating complex, consisting of factor IXa (FIXa) and the cofactor factor Villa (FVIIIa), the FXa-generating complex consisting of factor Vila (FVIIa) and tissue factor, and the thrombin-generating complex, consisting of FXa and the cofactor factor Va (FVa). The physiologic significance of these pathways is evident from genetic deficiencies that result in bleeding disorders. All the proteins involved in the coagulation cascade require post-trans­lational modifications for appropriate secretion, plasma half­ life, and function. The two most common genetic bleeding diseases involving this cascade are hemophilia A and B, which are due to deficiency in coagulation factors VIII and IX respec­tively. Recombinant DNA technology has provided the ability to produce safe and efficacious preparations of both FVIII and FIX for hemophilia replacement therapy. Gene therapy ap­proaches for these diseases are rapidly approaching and need to consider the requirement for proper post-translational modifi­cation in protein secretion and function.

The domain structures of the vitamin K-dependent coagulation factors FVII, FIX, FX, prothrombin, protein C, and protein S de­duced from their cDNA sequences demonstrate they contain common structural features (Figure 2.1). All contain a signal peptide that is required for translocation into the lumen of the endoplasmic reticulum (ER). This is followed by a propeptide that directs vitamin-K dependent g-carboxylation of the mature polypeptide. Upon transit through the trans-Golgi apparatus, the propeptide is cleaved away. The amino terminus of the ma­ture protein contains a g-carboxyglutamic acid-rich region (Gla) that includes a short a-helical stack of aromatic amino acids. Then there are two epidermal growth factor (EGF)-like domains. In FIX, protein C, and FX, the amino-terminal EGF domain contains b-hydroxyaspartic acid (Hya) at homologouslocations. The next region is the activation peptide (12-52 residues), which is glycosylated on asparagine residues and is re­leased by specific proteolysis accompanying activation. The re­mainder of the vitamin K-dependent protease comprises the serine protease catalytic triad, which is absent in protein S.

Regardless of what kind of doctor a student decides to become, a well-grounded understanding of disorders of the blood and the hematopoietic tissues is essential. Primary hematologic disorders are commonly encountered in community and hospital-based clinical practices, and a wide variety of other diseases come to attention by producing secondary abnormalities of the blood. Beyond their ev­eryday clinical importance, studies of hematologic diseases have yielded seminal insights into the molecular pathogenesis of cancer and basic aspects of stem cell biology. Lessons have had far-reaching influences on biomedical research and are beginning to shape the practice of molecular medicine. Plasma, the fluid phase of the blood, consists of water and solutes such as proteins, lipids, and electrolytes. The homeostatic mechanisms that regulate plasma volume, electrolytes, and lipids are beyond our scope. Here, our chief focus will be on the plasma proteins that are involved in the formation and dissolution of blood clots. The most important of these are the proteins of the coagulation cascade, certain coagulation cascade regulatory factors, von Willebrand factor, and proteins that promote the lysis of clots, such as plasmin. The laboratory tests that are used to assess these factors as well as the function of platelets, which have an essential role in hemostasis.

Under normal circumstances, the bone marrow is the only site of blood ccll production (hematopoiesis) following birth. Early in life, most bones contain hematopoietically active marrow, but by adulthood hematopoiesis is normally confincd to the axial skeleton, the proximal long bones, and the skull. The marrow is supplied by nutrient arteries, which divide and eventually give rise to venous sinusoids that are lined by endothelial cells and adventitial cells. The frond-like tissue between the sinusoids contains a mixture of fibroblasts, fat cells, mononu­clear cells (including lymphocytes and macrophages), and hematopoietic cell.

Xarelto Lawsuit News: More information about your search

Xarelto Lawsuit: Indications for performing a bone marrow examination include an unexplained decrease or increase in blood cell counts beyond the normal range and the pres­ence of abnormal cells in the blood (such as immature marrow precursors). Because myeloid elements (red cells, neutrophils, and platelets) have short life spans relative to lymphocytes, a decrease in marrow function, whatever the cause, affects these formed elements first. A decrease in all of the myeloid elements is called paticytopeuia and usually indicates the existence of a disorder that causes a decrease in marrow output. An increase in all of the myeloid elements is an unusu­al circumstance referred to as pancylosis.

Once released from the marrow, terminally differentiated myeloid elements (red cells, granulocytes, monocytes, and platelets) have defined fates and life spans. The story is quite different for T and B lymphocytes. After their release from the mar­row or the thymus, these cells circulate through the blood and home to the second­ary lymphoid tissues—the spleen, the lymph nodes, and the mucosa-associated lymphoid tissues (the most important of which are the Peyer patches of the small intestine and tonsillar tissues of the oropharynx). The anatomy of these tissues serves to optimize the probability that cells of the adaptive and innate immune systems will encounter pathogens and foreign antigens. If activated by antigen at these sites, T and B cells begin to proliferate and may undergo further differen­tiation to a variety of fates, which are dictated by factors produced locally at the site of the immune reaction. T cells can differentiate into effector T cells (helper and cytotoxic T cells), regulatory T cells, or memory T cells, whereas B cells can become memory B cells or plasma cells secreting one of a number of possible types of immunoglobulin.

The spleen has two chief functions: 1) it serves as a filter for particulate matter in the blood, and 2) it is a site of adaptive immune responses. Blood enters the splenic hilum through the splenic artery, which divides within the substance of the spleen to give rise to small arteries. During their course, these small arteries give rise to branches that are surrounded by lym­phoid follicles, organized collections of T cells and B cells that are poised to respond to immunologic stimuli; these constitute the splenic white pulp. The arteries eventually give rise to small, arborizing arterioles, which empty into the splenic red pulp, an interstitial space separated from the venous sinuses of the spleen by a basement membrane with slit-like openings.

The developmental origins of hematopoietic cells are complex and incompletely understood. Cells with the properties of hematopoietic stem cells (HSCs; described in the following section) arise several times in different tissues during prenatal development, producing successive waves of hematopoiesis (Fig. 2-1). Hematopoi­esis first appears around day 16 of gestation in the embryonic yolk sac; at this site, it is limited to the production of red cells, which are needed for oxygen trans­port in the newly developed circulatory system. Hematopoietic cells arise anew around 3 to 4 weeks of gestation in a portion of the ventral mesoderm referred to as the aorta-gonad-mesonephros region. HSCs derived from this region (and pos­sibly the yolk sac as well) are believed to migrate through the blood and take up residence in the liver, which becomes a hematopoietic organ at around 6 week.

Xarelto Lawsuit News: Additional Information and Resources

Xarelto Lawsuit: Some HSC divisions may be symmetric, such that both daughter cells either become HSCs or begin to differ­entiate into progenitors. Symmetric divisions that give rise to two HSCs may occur in the fetal liver, a stage of development during which HSC numbers increase. Symmetric divisions in which both daughter cells begin to differentiate into an early hematopoietic progenitor, a process termed commitment, may occur following periods of hematopoietic stress. Other HSC divisions are asymmetric, such that one cell remains an HSC, and the second commits to differentiation. Asymmetric cell divisions are dominant in the bone marrow, in which the num­ber of HSCs remains fairly constant. Details still remain to be worked out, but it appears that the potential of very early committed progenitors is first restricted to myeloid (red cell, granulocyte, and megakaryocyte) or lymphoid (B cell, T cell, and natural killer cell) differentiation. With subsequent divisions, the differentia­tion potential of progenitors is further refined, so that it is ultimately restricted to a single cell type.

Bone marrow HSCs normally spend most of the time in a resting state referred to as quiescence, only “awakening” to divide, at most, every few months. Quiescence may help to maintain the multipotent state and protect HSCs against the acquisition of mutations that could lead to transformation and cancer devel­opment. Under conditions of increased hematopoietic demand, however, HSCs in the marrow divide more frequently and are more likely to divide symmetri­cally, expanding their numbers. In extreme circumstances, substantial numbers of HSCs and early progenitors may leave the marrow and migrate to the liver, spleen, and lymph nodes, where they can produce extramedullary hematopoiesis.

HSC behavior in ways that are not yet completely understood. HSCs are resistant to stimulation by hematopoietic growth factors (described in the following sec­tion), possibly because niche factors actively promote quiescence. It may be that HSCs expand only when growth factors increase and quiescence factors decrease concomitantly. Another idea posits that HSC numbers are regulated by niche “vacancy,” such that HSCs expand their numbers only when open niches are avail­able. Under conditions of severe hematopoietic stress, it is possible that secondary niches appear in sites of extramedullary hematopoiesis, such as the liver.

Because HSCs are rare cells that are morphologically indistinguishable from lymphocytes, special means must be used to identify them. HSCs express particu­lar surface markers such as CD34 and actively pump out certain dyes, properties that can be used to identify populations of cells that are enriched for HSCs. How­ever, proof that viable HSCs are present in a sample requires functional testing. If a cell preparation can completely reconstitute long-term hematopoiesis when transfused into a host that has had its own marrow cells destroyed (e.g., by high doses of radiation), then it must contain HSCs, which can be quantified by serial dilution of the sample. Although this procedure, termed stem cell transplantation, was originally developed (and is still widely used) for experimental purposes, it was rapidly adopted as a means to treat a variety of diseases (described later in this chapter). It remains the only form of stem cell therapy that is widely used in clinical practice.

Xarelto Lawsuit News: News and Information from related Sources

Xarelto Lawsuit: Myelopoiesis (the production of myeloid elements—red cells, granulocytes, and platelets) is regulated at the level of myeloid progenitors by hematopoietic growth factors. As differentiation proceeds, myeloid progenitors lose multipotency and the capacity for self-renewal, but in turn acquire two other key properties: 1) an increased capacity for cell division, and 2) surface expression of specific receptors for hematopoietic growth factors. By controlling the growth and survival of com­mitted myeloid progenitors, growth factors regulate the production of red cells, granulocytes, and platelets from the marrow. Some growth factors, such as stem cell factor (also known as c-KIT ligand) and interleukin (IL)-3, have growth- and survival-promoting effects on multiple types of progenitors, whereas other factors, such as erythropoietin and thrombopoietin, have effects that are restricted to pro­genitors committed to a single line of differentiation.

Once an early progenitor commits to differentiate, what determines which kind of cell it becomes? Two models have been proposed. One supposes that factors pro­duced in the microenvironment instruct progenitors to differentiate along certain lines. In some instances, this appears to be true. For example, lymphoid progenitors exposed to factors that activate the Notch pathway become T cells, whereas, in the absence of Notch signals, these progenitors mainly become B cells instead, The other model supposes that progenitors randomly (stochastically) become competent to adopt particular fates and that hematopoietic growth factors act on this pool of cells to control their growth and survival. This model appears to hold for myeloid progen­itors, which (as described earlier) are regulated by hematopoietic growth factors.

One important group of disorders in which these regulatory mechanisms go awry is the various kinds of malignancies, cancers of hematopoietic cells. ‘Ihese cancers are commonly associated with acquired mutations that alter the function of the same transcription factors that control differentiation. In fact, mutations in particular transcription factors tend to be found in tumors composed of cells that correspond to the stage in development at which the affected tran­scription factor normally acts. For example, PAX5 mutations are found in tumors composed of early B-cell progenitors, whereas BCL6 mutations are confined to tumors derived from germinal center B cells. In general, cancer-specific mutations in transcription factors interfere with differentiation, holding cells in an immature state. In addition to transcription factor mutations, mutations in one or another component of the signaling pathways that arc normally activated by growth fac­tors are often found in hematopoietic cancers. These mutations typically stimulate signaling even in the absence of growth factors, permitting tumors to proliferate in a growth factor-independent fashion. These themes are expanded upon in later chapters describing the hematopoietic neoplasms.

Both models require that progenitors turn on the expression of a set of genes that allows hematopoietic differentiation to proceed. Experimental work with “knockout” mice has shown that certain transcription factors, proteins that associate with DNA and control gene expression, are critically important in directing differ­entiation along particular lines. For example, the loss of the transcrip­tion factor PAX5 specifically blocks B-cell development, while leaving other lineages intact. Similarly, loss of Notch 1, a unique type of receptor that also acts directly as a transcription factor, selectively blocks T-cell development, while mutations in C/EBPa block granulocytopoiesis. Other factors are required in early hematopoietic progenitors, and, as a result, their loss causes a complete failure of hematopoiesis. MLL is an example of one such factor. On the other end of the developmental spec­trum, some factors have no role in early progenitors or in lineage determination but arc instead required for the further differentiation of mature cells. For example, loss of the transcription factor BCL6 prevents antigen-stimulated B lymphocytes from maturing into germinal center B cells. Thus, hematopoiesis is orchestrated by a complex interplay between extrinsic factors (hematopoietic growth factors and local factors produced in the microenvironment) and factors intrinsic to hematopoietic progenitors (growth factor receptors and hematopoietic transcription factors).

Xarelto Lawsuit News: Information and News

Xarelto Lawsuit: Except for identical twins, the recipients of allogeneic SCT are reconstituted with cells that are genetically distinct from the host. In this situation, the trans­planted HSCs will be recognized as foreign and rejected by the patient’s immune system unless a “conditioning” regimen consisting of radiation and/or chemo­therapy is given. Conditioning serves two purposes: 1) it suppresses the recipients immune system, helping to prevent rejection of the transplanted cells, and 2) it destroys or displaces the recipients HSCs, creating vacancies in the marrow niche for the transplanted HSCs. The successful reconstitution of allogeneic SCT recipi­ents with HSCs from another individual has several important immunologic con­sequences. On the one hand, because lymphocytes derived from the transplanted HSCs recognize the recipients cells as foreign, recipients will develop potentially fatal graft-versus-host disease unless immunosuppressive drugs are given. On the other hand, when allogeneic SCT is performed in patients with cancer, donor lym­phocytes derived from the transplanted HSCs also recognize host cancer cells as foreign, producing a beneficial graft-versus-tumor effect.

An attractive but as yet unfulfilled use of SCT is as a means to deliver “gene therapy” to individuals with inherited hematopoietic disorders. In principle, it should be possible to repair genetic defects (for example, a defective P-globin gene encoding sickle hemoglobin) in stem cells in the laboratory and then reconstitute the patient with “corrected” HSCs through autologous SCT. Recent advances in reprogramming of somatic cells into stem cells with the capacity for hematopoiesis provide a reason for optimism about the long-term prospects of this approach. Epo is the most widely used growth factor. It is most effective when given to treat anemias associated with inappropriately low levels of Epo. These include the anemia of renal failure, in which the production of Epo is di­minished by damage to the kidney parenchyma, and the anemia of chronic inflammation, in which inflammatory cytokines suppress the production of Epo. Anemia of inflammation is common in patients with certain inflam­matory disorders and various forms of cancer. Epo is also used with varied success in patients with hematopoietic neoplasms, such as myelodysplastic syndromes, that are associated with ineffective hematopoiesis.

Our use of the term or terms Xarelto Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Xarelto Lawsuit News visit our site often.

Xarelto Lawsuit

Loryna Blood Clots News – 2/16/2012: Did you take Loryna? Please contact us today if you took Loryna and later experienced harmful side effects. We will connect you with a lawyer that is experienced in complex litigation that may be able to help you recover monetary damages.

Loryna Blood Clots: Although the pathogenic mechanisms are not definite, current models favor direct angiotoxicity involving endothelial and vascular smooth muscle cells, as well as impaired thrombolysis. Testing for homocysteine has not been recom­mended as a component of population screening for cardiovascular disease risk factors. The American Heart Association Nutrition Committee recommended measuring homocysteine levels in ‘‘high-riskpatients with a strong family history for premature atherosclerosis or with arterial occlusive diseases, particularly in the absence of other risk factors, as well as in members of their families’.

Interest in homocysteine levels among diabetics has grown over the past few years. Elevated homocysteine levels do not appear to be more common in type 1 diabet­ics, but a different situation may hold when renal impairment is present. Elevated levels are common in diabetes and are particularly associated with mild increases in serum creatinine and urinary excretion of albumin in type 1 diabetes. Young diabetics who smokehavebeenreported to have higherhomocysteine levels than diabetic nonsmokers. Similarly, the Hoorn Study in the Nether­lands demonstrated very strong associations between elevated homocysteine and death and disease in a nested case-control study that included approximately 800 subjects. In this study, the relative odds for mortality was similar for elevated homocysteine (>14 ^mol/L), hypertension, current smoking, and elevated choles­terol (>200 mg/dL). The authors report emphasized that the homocysteine associ­ations were stronger in diabetic than in nondiabetic participants.

While mean levels of homocysteine are approximately 10 ^mol/L in healthy adults and 14 to 15 ^mol/L in coronary disease cases, higher levels are commonly observed in persons with end-stage renal disease, where levels are typically in the 20 to 30 ^mol/L range. These elevations are often present despite regular use of folate supplementa­tion and demonstration of normal folate levels in the plasma. Recent cross­sectional data from Rhode Island dialysis patients suggest that elevated homo­cysteine levels are present even after folate fortification was instituted, and clini­cal trials of high-dose folate supplementation for renal patients have been suggested as a tactic to prevent atherosclerotic disease in this high-risk patient group.

Loryna Blood Clots News: More information about your search

Loryna Blood Clots: New factors associated with increased risk for coronary heart disease arouse great interest and enthusiasm, kindling the hope that we may enhance identification of individuals at risk for CHD. Important concerns are that such metabolic factors be biologically plausible, measurable, repeatable, strong, graded, and treatable (37-39). Measurement issues include accuracy and precision for the factor in the laboratory and evidence of low or modest variability in the clinical setting. If the laboratory or biological variability is very large, the utility of the measurement for predictive purposes is seriously reduced.

Many years of experience and stan­dardization of measurements are available for some vascular risk factors, and less experience is available for homocysteine. New risk factors may provide clues to pathogenesis and in some instances may improve our ability to predict disease. The ability to predict new vascular disease events should be demonstrated after consideration of the core set of factors that are currently available, including age, sex, blood pressure, cholesterol or LDL cholesterol, HDL cholesterol, smoking, and diabetes mellitus. This criterion is often not met in new investigations and considerable experience and relatively large data sets and follow-up may be nec­essary to assure that new factors, such as homocysteine, prove useful in predicting vascular disease risk.

Elevated homocysteine levels may be accompanied by decreased blood levels and intake of folate, vitamin B₆, or vitamin B₁₂. These vitamins are important cofactors in the metabolism of homocysteine, and border­line deficiencies are relatively common, affecting approximately 30% of the el­derly participants in the Framingham Heart Study. Greater intake of these vitamins in the diet, with supplements in the form of multivitamins, or through fortification of foods, has led to less vitamin deficiency and a decrease in the prevalence of elevated homocysteine levels. Fortification of the food supply in the United States with folate was announced in early 1996 with a mandated enactment date of January 1, 1998. Analyses of homocysteine and folate levels before and after fortification have been undertaken in Framingham Heart Study participants and showed a dramatic decline in the prevalence of low folate levels, a reduction in the prevalence of elevated homocysteine from approximately 20 to 10%, and a modest decrease in mean homocysteine levels from approximately 10 to 9 |J.mol/L.

Antiphospholipid antibodies (APLA) are a heterogeneous group of autoantibod­ies associated with both arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia. They can occur either in association with other auto­immune conditions, most frequently systemic lupus erythematosus (SLE), or in isolation, a condition known as the primary antiphospholipid antibody syndrome. In the research laboratory, many antiphospholipid antibodies (with varying epi­tope specificity) can be identified. However, in clinical practice, the antiphospho­lipid antibodies are divided into two large groups, the lupus anticoagulants and the anticardiolipin antibodies.

Loryna Blood Clots News: Additional Information and Resources

Loryna Blood Clots: Lupus anticoagulants or nonspecific inhibitors interfere with the assembly of procoagulant complexes. In vitro, these antibodies are associated with the pro­longation of phospholipid-dependent blood-clotting times. Characteristically, clotting times return to normal with the addition of exogenous phospholipid. Lu­pus anticoagulants may demonstrate specificity for blood-clotting proteins, in particular prothrombin. However, the mechanism by which they promote throm­bosis is unknown. Lupus anticoagulants are likely associated with a high risk of first and recurrent thrombosis as well as recurrent pregnancy loss.

APLA are found in about 20% of patients presenting with venous thromboembo­lism, in about 10% of patients presenting with first ischemic stroke, and in approximately 5 to 10% of young people presenting with first myocardial infarction. Their prevalence in the unselected population is unknown; reported rates vary widely with the test system used and the population being studied. About 30% of individuals with systemic lupus erythematosus have an APLA. Low-titer anticardiolipin antibodies are frequently detected in otherwise well individuals; repeat testing reveals a high rate of spontaneous resolution.

Many ACA are specific for beta-2 glycoprotein-1 in concert with cell-surface anionic phospholipid (6) and are detected and quantified using accurate ELISA (7,8). The levels of IgG, IgA, and IgM antiphospholipid antibodies can be quanti­fied and are usually reported in phospholipid antibody units (PL units). The iso­type and subgroup specificity of ACA appears to be important. For example, high-titer IgG ACA is associated with a high risk of clinical complications, while the clinical significance of IgM or IgA ACA, even when present in high titer, is less clear. Anticardiolipin antibody testing is notoriously inaccurate; both within- and between-center reliability is poor.

LAC are a heterogeneous group of autoantibodies, which prolong the clot­ting time in a variety of assays and may demonstrate specificity for beta- 2 glycoprotein-1. LAC do not prolong clotting times in assays in which phospholipid is present in excess. This suggests that LAC inhibit in vitro coagula­tion by interfering with the assembly of procoagulant complexes on phospholipid surfaces. This observation also forms the basis for the test for LAC—a prolonged clotting time, in a phospholipid-limited assay system, that normalizes with the addition of excess phospholipid confirms the presence of LAC. Anecdotal experi­ence suggests that lupus anticoagulants are much less common than anticardio- lipin antibodies, that they are infrequently transient, and that they are associated with a high risk of complications, although none of these observations has been adequately studied. Furthermore, laboratory assays for lupus anticoagulants.­

Loryna Blood Clots News: News and Information from related Sources

Loryna Blood Clots: For the prevention of thromboembolism, high-intensity warfarin (target INR > 2.8) has been evaluated in five settings: patients with tissue heart valves patients with acute deep vein thrombosis; patients with APLA (16,29,30); patients with previous stroke; and patients with coronary artery disease (26). High-intensity warfarin was not more effective than standard-intensity warfarin in the first two studies: these results contrast with those reported in patients with coronary artery disease in whom high-intensity warfarin was associated with a reduced risk of death, myocardial infarction, and stroke at a cost of an increased risk of hemorrhage. In patients with previous stroke, the SPIRIT study demonstrated that, compared with aspirin (80 mg/ day), warfarin administered with a target intensity of 3.0 to 4.5 resulted in a significant increase in the risk of hemorrhage (hazard ratio 2.3; 95% CI, 1.6 to 3.5). The incidence of bleeding increased by a factor of 1.43 (95% CI, 0.96 to 2.13) for each 0.5-unit increase of the achieved INR. A similar increase in the risk of hemorrhage was reported in the other investigations of warfarin adminis­tered with a target intensity of more than 3.0.

The annual risk of fatal, major, and minor bleeding in patients receiving warfarin with a target INR of 2.0 to 3.0 is 0.4% to 1.0%, 1.3% to 6.6%, and 8% to 22%, respectively, rates approximately 5 times those seen in patients not re­ceiving warfarin. The risk of hemorrhage varies with the duration of anticoagulant therapy, with the greatest risk in the first year of therapy. In addition, the major bleeding rate increases in proportion to the INR. Based on many prospective studies, the annual risk of major hemorrhage in a patient treated with long-term warfarin with a target INR of 2.0 to 3.0 is likely to be 3% or less. The risk increases as the INR target range is increased beyond 3.0. Based on a comprehensive review of the literature, Landefeld esti­mated that the risk of hemorrhage increases threefold when the target INR is increased from 2.5 to 3.5, a figure also reported by the SPIRIT investigators. This potential for warfarin resistance explains why most ongoing trials eval­uating long-term, low-dose warfarin regimens (INR 1.5-2.0) have excluded pa­tients with known ACA syndromes.

A congenital or acquired hypercoagulable state should be suspected in all patients presenting with unusual forms of thrombosis or in whom thrombosis occurs at a young age in the absence of identifiable risk factors. Hypercoagulable states associated with venous thrombosis include activated protein C resistance (with or without factor V Leiden), the prothrombin gene 20210A mutation, and defi­ciencies of protein C, protein S, or antithrombin. Hyperhomocysteinemia can be either congenital or acquired and is associated with both arterial and venous thrombosis, as are the antiphospholipid antibodies. Unexpected arterial thrombo­sis in otherwise well patients can be associated with hyperhomocysteinemia or antiphospholipid antibodies.

All patients with unexplained venous thrombosis, in particular those with thrombosis in unusual sites (such as the cerebral veins or mesenteric veins), should be screened for an antiphospholipid antibody. Both a lupus and an anticar- diolipin antibody should be sought. Testing should be carried out in accordance with the recommendations of the International Society of Thrombosis and He- mostasis, with appropriate confirmatory assays for suspected lupus anticoagu­lants. Patients with arterial thrombosis should also be screened for a hypercoag- ulable state if their thrombosis has occurred at a young age, or in an unusual location in the absence of other risk factors such as valvular heart disease. Testing of cholesterol and triglyceride levels, homocysteine levels, preferably in the fast­ing state, and antiphospholipid antibodies may reveal a treatable cause for their episode of arterial thrombosis.

Loryna Blood Clots News: Information and News

Loryna Blood Clots: Many questions remain unanswered in patients with antiphospholipid antibodies. First, many patients, particularly those with systemic lupus erythematosus, are screened for the presence of an antiphospholipid antibody despite their never having had an episode of thrombosis. When detected, the clinical importance of the antibody is unknown. As a result, some such patients (who are suspected to have a high risk of first thrombosis) are treated with warfarin with varying INR target ranges, while others are treated with aspirin or other antiplatelet agents, and many receive no antithrombotic prophylaxis. To address the need for routine antithrombotic prophylaxis in this problematic patient population, a large, ran­domized clinical trial is currently being carried out. Within this study, adults and children, with both an antiphospholipid antibody and systemic lupus erythemato­sus, are allocated to long-term warfarin with a target INR of 2.0, or no therapy. The primary outcome measure of the study is the rate of objectively confirmed arterial and venous thrombosis.

A second frequently encountered clinical problem is determining the opti­mal intensity of warfarin anticoagulation in patients with an APLA and a history of previous thrombosis. Evidence-based treatment recommendations are not available, and there is a large variation in practice habits for patients with this problem. Two large, multicenter trials are currently under way which will address this issue. In both, patients with a persistently positive APLA and a history of arterial or venous thrombosis are allocated to receive warfarin with a target INR that exceeds 3.0 versus lower intensity anticoagulation. These studies will provide guidance for the optimal intensity of warfarin therapy and reliable esti­mates of the risk of recurrent thrombosis in patients treated with warfarin with a target intensity of less than 3.0.

There is a large body of evidence that patients with antiphospholipid antibodies have an increased risk of pregnancy complications, including pregnancy loss (36-38). The pathophysiology of recurrent pregnancy loss in such patients is not completely understood, and current theories revolve around placental pathol­ogy leading to fetal hypoxia. These theories invoke either placental vascular thrombosis leading to placental infarction; abnormal uteroplacental vascular con­version, as in spiral artery vasculopathy; or a combination of the two. In particular, recent interest has focused on changes in cell-surface annexin V in response to antiphospholipid antibodies. Reductions in the levels of annexin V might be associated with the development of a procoagulant state in the uterus.

In an effort to improve the rate of successful pregnancy outcomes, a variety of interventions, including low-dose aspirin (ASA), heparin, prednisone, intrave­nous immunoglobulins, and combinations of these therapies, have been used. It is plausible that antithrombotic therapy (heparin and aspirin) might reduce the risk of pregnancy loss, if this loss is due to placental vascular thrombosis. Prednisone has anti-inflammatory and immunosuppressive properties, which might reduce the risk of fetal loss either by reducing the production of APLA or by reducing placental vascular changes that promote a prothrombotic state. Intravenous immunoglobulin is believed to improve the likelihood of successful pregnancy outcomes in patients with APS by either blocking the activity of autoantibodies (mediated by passively transferred anti-idiotypic anti­bodies) or by immune modulation (up-regulation of suppressor T-cell function); both antibody blockade and immune modulation could theoretically prevent placental thrombosis by reducing the levels of APLA.

Our use of the term or terms Loryna Blood Clots News is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Blood Clots News visit our site often.

Loryna Blood Clots

Loryna Class Action Lawsuit News – 2/16/2012: Loryna may be linked to serious negative side effects. If you took Loryna and believe you suffered negative side effects as a result, contact us today so that we can make arrangements for a free consultation with a law firm that is investigating cases related to the side effects of Loryna.

Loryna Class Action Lawsuit: An emerging concept of GP IIb/IIIa inhibition, based on evidence from two trials, is that these agents appear to be able to reduce the size of an evolving non-ST-elevation MI, and potentially prevent the development of myocardial ne­crosis. In the troponin substudy of PRISM-PLUS, patients randomized to tiro- fiban plus heparin and aspirin had a significantly lower peak troponin level as compared with patients who received heparin and aspirin alone. This observation was made among patients who had a negative CK-MB on admis­sion. In PURSUIT, using peak CK-MB as a measure of infarct size, it was observed that infarct size, either the index MI or a recurrent MI, was signifi­cantly smaller in patients treated with eptifibatide. Thus, when using these potent antiplatelet therapies early in the course of treatment, there appears to be an immediate reduction of the severity of the presenting illness, which is similar to the beneficial effect of chronic aspirin use in reducing the severity of the pre­senting acute coronary syndrome.

Thrombolytic therapy has dramatically reduced mortality following acute myo­cardial infarction. Its benefit is due to early achievement of infarct-related artery patency, which limits myocardial infarct size, decreases left ventricular dysfunc­tion, and improves survival. While thrombolytic therapy has proved to be a major advance in the treatment of patients with acute myocardial infarction, current regimens are limited by failure of initial reperfusion, inadequate perfusion with delayed flow (TIMI grade 2 flow), reocclusion, and reinfarction in sig­nificant percentages of patients. Because these problems are associated with increased subsequent mortality, and because platelets play a central role in failed reperfusion, reocclusion, and reinfarction, attention has turned to the promising glycoprotein IIb/IIIa inhibitors.

In the setting of ST-elevation MI, IIb/IIIa inhibition was first used following thrombolysis in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI)-8 trial using abciximab following tissue plasminogen activator (tPA). A consistent dose-dependent inhibition of platelet aggregation was observed and major bleeding was not increased. Eptifibatide was tested in the Integrilin to Manage Platelet Aggregation and Combat Acute Myocardial Infarction (IMPACT-AMI) trial. In addition to accelerated, full-dose tPA, aspirin, and heparin, patients were randomized to ep­tifibatide, at one of six doses, or placebo. The highest dose of eptifibatide ap­peared to improve the 90-min rate of TIMI grade 3 flow (66 vs. 39% for placebo; p = 0.006). More recently, a pilot study combined full-dose streptokinase (1.5 million U/h) and three doses of eptifibatide (180-^g/kg bolus and either 0.75-, 1.33-, or 2.0-^g/kg/min infusion for 24 h) or placebo. Adding the IIb/IIIa inhibitor led to a modest improvement in early complete reperfusion (TIMI grade flow 3 at 90 min) from 38% with placebo to approximately 50% with eptifibatide. The highest dose of eptifibatide was associated with increased bleeding and was discontinued. Further testing of eptifibatide is planned with reduced-dose thrombolytic agents.

The combination of a reduced-dose fibrinolytic agent and a GP IIb/IIIa inhibitor was tested in the TIMI-14 trial, using tPA, streptokinase, and reteplase; in SPEED (Strategies for Patency Enhancement in the Emergency Department) using rete- plase; and in INTRO-AMI and several ongoing trials. In the TIMI-14 trial dose-ranging phase, 681 patients with ST-segment- elevation MI meeting with standard eligibility criteria were randomized within 12 h of onset of chest pain to receive one of four reperfusion regimens (each with several dose levels): accelerated (full-dose) tPA alone (the control arm); reduced-dose tPA plus abciximab; reduced-dose streptokinase plus abciximab; or abciximab alone. All patients received aspirin and heparin, with the initial heparin dosage being 70-U/kg bolus and a 15-U/kg/h infusion in the tPA control arm, and 60-U/kg bolus and a 7-U/kg/h infusion in the abciximab groups.

Loryna Class Action Lawsuit News: Additional Information and Resources

Loryna Class Action Lawsuit: Abciximab alone was associated with a rate of TIMI grade 3 flow at 90 min of 32% and patency rate of 48% (43). The combination of streptokinase and abciximab produced only slight improvement in 90-min TIMI grade 3 flow: 42% in the 0.5-MU group; 39% in the 0.75-MU group; and 47% in the 1.25-MU group. The 1.5-MU regimen plus abciximab was discontinued after four of six patients developed a major hemorrhage, one of whom had an ICH. Of the various dosing regimens of tPA tested, the best angiographic results were obtained using a 50-mg dose given as a 15-mg bolus and a 35-mg infusion over 60 min. The rate of TIMI grade 3 flow at 90 min was 77% compared with 62% for tPA alone (p = 0.02). Overall patency was achieved in 93% of patients with the combination of abciximab and half-dose tPA compared with 78% for full-dose tPA alone (p = 0.09). An even greater difference was observed at 60 min: accelerated tPA achieved only 43% TIMI grade 3 flow at 60 min compared with 72% for 50-mg tPA plus abciximab (p = 0.0009). Major hemorrhage was similar (approximately 6%) among the tPA plus abciximab and control groups. In-hospital mortality was low in all groups, ranging from 3 to 5%.

The Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI)-16 trial tested the oral Il/IIIa inhibitor, orbofiban, in patients with acute coronary syndromes. This trial enrolled 10,288 patients at 888 hospitals in 28 countries. The inclusion criteria were onset of an acute coronary syndromes within 72 h, defined as an episode of rest ischemic pain lasting at least 5 min associated with either positive cardiac enzymes (i.e., an acute MI), ECG changes, or a prior his­tory of coronary or vascular disease. Exclusion criteria included renal insuffi­ciency (creatinine >1.6 mg/dL, increased high bleeding risk, or need for oral anticoagulation. All patients received 150 to 162 mg of ASA daily and were randomized, in double-blind fashion, to one of two doses of orbofiban or placebo. In one group, orbofiban was administered as 50 mg twice daily throughout the trial (50/ 50 group); in the other group, 50 mg was given twice daily for the first 30 days (the highest risk period), and was reduced to 30 mg twice daily for the remainder of the trial (50/30 group). Other treatments were at the discretion of the pa­tient’s physician. The primary endpoint was a composite of death, MI, recurrent ischemia leading to rehospitalization or urgent revascularization, or stroke. The planned sample size was 12,000 patients, but the trial was terminated early after an unexpected finding of increased mortality at 30 days in one of the orbofiban groups.

Mortality through 10 months was 3.7% for the placebo group versus 5.1% in the 50/30 group (p = 0.008) and 4.5% in the 50/50 group (p = 0.11). There were no differences in the primary composite endpoint at 10 months (22.9, 23.1, and 22.8%, for the placebo, 50/30, and 50/50 groups, respectively). Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2.0, 3.7 (p = 0.0004), and 4.5% (p < 0.0001) of patients, respec­tively. Exploratory subgroup analyses did identify that patients who underwent percutaneous coronary intervention had a lower mortality and a significant reduc­tion in the composite endpoint (p = 0.001) with orbofiban. Two substudies from OPUS-TIMI-16 found that orbofiban led to increases in measures of platelet activation, notably P-selectin. These data are con­sistent with observations of other agents, which induced an apparent prothrom- botic effect, with increases in measures of platelet activation and increases in platelet aggregation when drug levels were low. Interestingly, in the TIMI-12 trial, no increase in P-selectin was observed with sibrafiban therapy. Active research is ongoing, but these initial studies suggest that there may be differences among the various oral IIb/IIIa inhibitors with regard to potential prothrombotic effects.

The Evaluation of oral Xemilofiban in Controlling Thrombotic Events (EXCITE) trial studied xemilofiban in 7232 patients undergoing PCI with either stenting or balloon angioplasty without adjunctive intravenous IIb/IIIa inhibition. Patients were randomized in a double-blind fashion to receive one of two doses of xemilofiban or placebo: All the xemilofiban patients received a first 20-mg dose 30 to 90 min prior to PCI, followed by either 10 or 20 mg three times daily for 6 months. The primary endpoint—death, MI, or urgent revascularization at 6 months—occurred in 13.6% of patients in the placebo group, 14.1% of patients in the xemilofiban 10-mg group, and 12.6% of patients in the xemilofiban 20­mg group (p = NS) (78). There was a trend toward fewer periprocedural MIs over the first 48 h following PCI, but this benefit was not sustained at 30 days or 6 months. Mortality at 6 months was 1.0% for placebo, 1.6% for the 10­mg xemilofiban dose group, and 1.1% in the 20-mg dose group. Major bleed­ing was significantly more common in the xemilofiban-treated patients. Thus, xemilofiban did not significantly reduce cardiac events in this patient popu­lation.

Loryna Class Action Lawsuit News: News and Information from related Sources

Loryna Class Action Lawsuit: The second Symphony trial was terminated prematurely at the time the results from the first Symphony trial were available (and not due to safety issues). It compared the combination of low-dose sibrafiban plus aspirin vs. high-dose si­brafiban (without aspirin) vs. aspirin alone in 6671 patients with stabilized acute coronary syndromes. With an average follow-up of 90 days, the primary endpoint, death, MI, or severe recurrent ischemia, was not different among the three groups: 10.5% in the high-dose sibrafiban group; 9.2% for low-dose sibrafiban plus aspi­rin vs. 9.3% for aspirin alone. In this trial (but not in the larger first Symphony trial), mortality was significantly higher with the high-dose sibrafiban group: 2.4 vs. 1.7% for the low-dose sibrafiban plus aspirin group vs. 1.3% for placebo. Recurrent MI followed a similar pattern: 6.9% for high-dose sibrafiban, 5.3% for the low-dose plus aspirin group, and 5.3% for aspirin. Major bleeding was more common with high-dose sibrafiban (4.6%), and higher still for the combination of low-dose sibrafiban plus aspirin (5.7%) vs. 4.0% for aspirin alone.

It is an exciting time for the practicing physician given the availability of this important new therapy that can significantly reduce death, MI, or refractory ischemia/urgent revascularization. The benefits apply to essentially all patients undergoing PCI, thereby becoming a new standard of care in this setting. For the huge number of patients with unstable angina and non-ST-elevation MI, IIb/ IIIa inhibition will significantly reduce recurrent ischemic events. The trials to date have targeted the higher risk unstable angina patients—those with ECG changes or positive cardiac enzymes, and thus these are the patients in clinical practice who should be targeted for early use of IIb/IIIa inhibitors.

Platelets are integrally involved in the thrombotic complications of atherosclero­sis. Their contribution to thrombosis complicating a ruptured atherosclerotic plaque is well established. Interference with platelet function, therefore, should help to prevent thrombotic occlusion of arteries affected by atherosclerosis. In­deed, numerous studies have demonstrated that antiplatelet agents decrease ad­verse cardiovascular events in patients with atherosclerosis. This chapter will focus on three such antiplatelet agents: aspirin, ticlopidine, and clopidogrel. It will include a brief review of platelet function followed by a discussion of the mechanisms of action of these antiplatelet drugs. Thereafter, clinical evidence supporting the notion that antiplatelet agents reduce adverse cardiovascular events in patients with atherosclerosis will be presented.

The three principal events in the formation of a platelet plug include platelet adhesion, activation, and aggregation. Platelets normally circulate in an inacti­vated state. Vascular injury and disruption of the endothelial lining initiates the process of platelet adhesion, in which platelets are deposited on the intimal surface of blood vessels. Among the most important substances to mediate platelet adhesion to the vascular surface is von Willebrand factor. It binds suben­dothelial collagen to the platelet glycoprotein Ib-IX-V receptor. Binding of plate­lets to the vascular surface prompts an intracellular signaling mechanism, includ­ing the metabolism of arachidonic acid to thromboxane A₂. In addition, the platelets release constituents of their alpha and dense granules such as p-selectin.

Loryna Class Action Lawsuit News: Information and News

Loryna Class Action Lawsuit: Aspirin inhibits arachidonic acid metabolism and prevents the formation of thromboxane A₂ by irreversibly inhibiting cyclooxygenase via acetylation of a serine moiety. Platelet inhibition occurs approximately 60 min following the oral ingestion of aspirin. The inhibitory effects of platelets last the life of a platelet, which is approximately 10 days. Hemostatic recovery following a single dose of aspirin occurs as new platelets are formed and enter the circulation. Both ticlopidine and clopidogrel are thienopyridines. These inhibit the function of platelet ADP receptors and thereby limit conformational changes in the glycoprotein IIb/IIIa receptor. Inhibition of platelet aggregation occurs ap­proximately 1 to 2 days following administration of these drugs, and 40 to 60% inhibition of ADP-induced aggregation is observed 3 to 5 days following inges­tion. Platelet function is restored approximately 3 to 4 days after discontinua­tion of ticlopidine or clopidogrel.

The beneficial effects of aspirin on cardiovascular outcome in patients with ath­erosclerosis is well established. The Antiplatelet Trialists’ Collaboration per­formed a metanalysis of over 73,000 patients with clinical manifestations of ath­erosclerosis such as acute myocardial infarction, prior myocardial infarction, or prior stroke or transient ischemic attack, in which patients were treated with either antiplatelet therapy or a control. The most widely studied antiplatelet drug was aspirin. Overall, antiplatelet therapy was associated with a 25% odds reduc­tion for the aggregate endpoint of stroke, myocardial infarction, or vascular death. The studies included in this metanalysis, as well as some more recent studies, highlight the efficacy of aspirin in reducing cardiovascular morbidity and mortality in patients with atherosclerosis. Some of the larger studies involving patients with coronary artery disease, cerebrovascular disease, or peripheral arte­rial disease are described below.

In the Antiplatelet Trialists’ Collaboration, antiplatelet therapy, primarily aspirin, was associated with a 29% odds reduction for stroke, myocardial, or vascular death among approximately 20,000 patients with acute myocardial infarction and a 25% odds reduction for these adverse events among approximately 20,000 pa­tients with prior myocardial infarction. The largest trial for acute myocardial infarction included in the Antiplatelet Trialists’ Collaboration was the Second International Study of Infarct Survival (ISIS-2), which randomized over 17,000 patients with acute myocardial infarction to aspirin, streptokinase, both, or neither. Compared to placebo, aspirin was associated with a 23% risk reduction for vascular death, a 50% reduction for nonfatal reinfarction, and a 46% reduction for nonfatal stroke 5 weeks after randomization. The combination of streptokinase and aspirin was more effective than either agent alone in reducing vascular death. The efficacy of aspirin in preventing coronary reocclusion follow­ing thrombolysis for acute myocardial infarction is supported by a metanalysis of 32 studies. Reocclusion occurred in 11% of 419 patients treated with aspirin versus 25% of 513 patients not treated with aspirin, and recurrent ischemic events occurred in 25% of 2977 patients treated with aspirin compared to 41% of 721 patients who were not treated with aspirin.

Several large trials have demonstrated the efficacy of aspirin in preventing myocardial infarction and death in patients with unstable angina. A Veterans Administration Cooperative study randomized 1256 men with unstable angina to aspirin or placebo for 12 weeks. The incidence of fatal or nonfatal myocardial infarction was reduced by 51% in the group treated with aspirin compared to the group treated with placebo. A Canadian multicenter trial randomized 555 patients with unstable angina to aspirin, sulfinpyrizone, both, or neither to 24 months of treatment. The incidence of fatal or nonfatal myocardial infarction was 8.6% in the groups receiving aspirin compared to 17% in the groups not receiving aspirin, resulting in a 51% risk reduction with aspirin. Theroux et al. compared the efficacy of aspirin, intravenous heparin, both, or neither in 479 patients with unstable angina. Approximately 6 days following randomization, myocardial infarction had occurred in 11.9% of patients who received neither aspirin nor heparin, in 3.3% who received any aspirin, in 0.8% of those who received only heparin, and in 1.6% of patients who received both aspirin and heparin. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden (R.I.S.C.) randomized 796 men with unstable angina or non-Q-wave myocardial infarction to aspirin or placebo. After 1 year, myocardial infarction occurred in 21.4% of patients treated with placebo and in 11% of patients treated with aspirin. Thus, aspirin treatment reduced the risk of nonfatal or fatal myocardial infarction by 48%.

Our use of the term or terms Loryna Class Action Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Class Action Lawsuit News visit our site often.

Loryna Class Action Lawsuit

Loryna Class Action News – 2/16/2012: If you were prescribed Loryna and have suffered negative side effects, please contact us today so that we can put you in touch with an attorney to advise you of your legal rights.

Loryna Class Action: The findings from the observational studies that hormone users are at generally lower risk from coronary disease do not necessarily imply cause and effect. Women and their physicians decide on estrogen therapy. Often the health status of the woman will have an important influence on this decision and on the results of studies that examine these women. Thus, some have argued that hormone use is merely a marker rather than a cause of good health. Most of the observational studies reviewed here have provided some in­formation bearing on this critical point. The Nurses’ Health Study tried to evalu­ate whether increased medical care of women using postmenopausal hormones might be responsible for the benefit observed. In an analysis limited to women who reported regular physician visits (50% of the cohort), results were sim­ilar to those found in the larger population of all subjects: the relative risk for major coronary heart disease was 0.52 (95% CI, 0.37-0.74) for current hormone use.

Another approach is to examine the risk profile of estrogen users and non­users to determine whether the differences, if any, are sufficient to explain the large decrease in risk among estrogen users. Barrett-Connor observed that, in a cohort of postmenopausal women, those taking estrogens reported more in­tensive health-care behavior, including frequent screening tests such as blood cholesterol measurement and mammograms. An examination of determinants of estrogen therapy in 9704 women participating in a large, multicenter study of osteoporotic fractures found that hormone users tended to be better educated, less obese, and drank alcohol and participated in sports more often than nonusers. Similarly, in a prospective study of randomly selected premenopausal women, observed a better cardiovascular risk factor profile prior to hormone use among the women who subsequently took hormones at menopause than among women who did not.

For hormone users compared to nonusers and, after further adjustment for high blood pressure, history of angina, MI, or stroke, alcohol use, smoking, body mass index, and age at menopause, the relative risk was virtually the same (RR = 0.79; 95% CI, 0.71-0.88), implying an equivalent risk status for users and nonusers. In addition, to further examine this issue, the Nurses’ Health Study conducted an analysis limited to a subgroup of low-risk women (i.e., those with no diagnosis of hypertension, diabetes, or high serum cholesterol who were nonsmokers and had a Quetelet’s Index below 32 kg/m²). Even with such restrictions, the relative risk for coronary disease was almost 40% lower for current hormone users. In summary, to explain the overall benefit of hormone therapy as a result of con­founding by health status, one would have to presume unknown risk factors which are extremely strong predictors of CHD and very closely associated with estrogen use.

LMWHs, like UFH, bind a cofactor called antithrombin to produce their predominant anticoagulant effect. Binding is mediated through a unique pentasac­charide sequence of the mucopolysaccharide that increases by 1000-fold both the interaction between antithrombin and thrombin (factor II_a), and the interaction between antithrombin and factor Xa. However, a minimum chain length of 15 to 18 saccharides (corresponding to a molecular weight of > 5400 daltons) is required to inactivate thrombin. In contrast, inhibition of factor Xa can occur with short polysaccharide chains. Thus, one potentially important distinc­tion between UFH and LMWH, and among LMWHs themselves, is the varying ratio of factor Xa to factor IIa. The factor Xa:IIa activity for UFH is approxi­mately 1.2, while ratios for the various LMWH preparations vary from 2 to 4. Table 1 lists LMWHs in order of anti Xa:IIa ratio.

Loryna Class Action News: Additional Information and Resources

Loryna Class Action: The ESSENCE study was a double-blind, placebo-controlled trial that ran­domly assigned 3171 patients with angina at rest or non-Q-wave myocardial in­farction to receive 2 to 8 days therapy with either 1 mg/kg of enoxaparin subcuta­neously twice daily or continuous intravenous UFH. At 14 days, the risk of death, myocardial infarction, or recurrent angina was significantly lower in the patients assigned to enoxaparin than in those assigned to UFH (16.6% vs. 19.8%; p = 0.019). At 30 days, the risk of this composite endpoint remained significantly lower in the enoxaparin group (19.8% vs. 23.3%; p = 0.016). The need for revas­cularization procedures at 30 days was also significantly less frequent in the pa­tients assigned to enoxaparin (27.1% vs. 32.2%; p = 0.001). The 30-day inci­dence of major bleeding complications was 6.5% in the enoxaparin group and 7.0% in the unfractionated-heparin group, but the incidence of bleeding overall was significantly higher in the enoxaparin group (18.4% vs. 14.2%; p = 0.001), primarily because of ecchymoses at injection sites. Thus, the ESSENCE trial indicates that enoxaparin plus aspirin is more effective than UFH plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase. This benefit was associated with an increase in minor, but not major, bleeding.

In TIMI-11B, 3910 patients with unstable angina or non-Q-wave MI were randomized to either intravenous UFH for 3 to 8 days followed by subcutaneous placebo injections, or enoxaparin during both the acute phase (initial 30-mg IV bolus followed by injections of 1.0 mg/kg every 12 h for 3 to 8 days) and outpa­tient phase (injections every 12 h for up to 43 days of 40 mg for patients weighing >65 kg and 60 mg for those weighing <65 kg). The primary endpoint (death, myocardial infarction, or urgent revascularization) occurred by 8 days in 14.5% of patients in the UFH group and 12.4% of patients in the enoxaparin group (OR 0.83 [0.69 to 1.00]; p = 0.048) and by 43 days in 19.7% of the UFH group and 17.3% of the enoxaparin group (OR 0.85 [0.72 to 1.00]; p = 0.048). During the first 72 h and also throughout the entire initial hospitalization, there was no differ­ence in the rate of major hemorrhage in the treatment groups. During the outpa­tient phase, major hemorrhage occurred in 1.5% of the group treated with placebo and 2.9% of the group treated with enoxaparin (p = 0.021). Consistent with the ESSENCE findings described above, the results of the TIMI-11B study demon­strate that enoxaparin is superior to UFH in reducing a composite of death and serious cardiac ischemic events during the acute management of patients present­ing with unstable angina, but does not cause a significant increase in the rate of major hemorrhage.

Last, the FRAXIS trial (29) randomized 3468 patients in a double-blind fashion to one of three treatment regimens: UFH (5000 IU bolus, followed by an infusion for 6 ± 2 days); nadroparin for 6 days (nadroparin 86 anti-Xa IU/kg IV bolus, followed by twice-daily subcutaneous injections for 6 ± 2 days); or nadroparin for 14 days (same dose as the prior group for 14 days). No statistically significant differences were observed among the three treatment regimens with respect to the primary outcome (cardiac death, myocardial infarction, refractory angina, or recurrence of unstable angina at day 14). The absolute differences between the groups in the incidence of the primary outcome were: -0.3% (p = 0.85) for the nadroparin 6-day group vs. the UFH group, and +1.9% (p = 0.24) for the nadro- parin 14-day group vs. the unfractionated heparin group. Furthermore, there were no significant intergroup differences regarding any of the secondary efficacy out­comes. However, there was an increased risk of major hemorrhage in the nadro­parin 14-day group compared with UFH (3.5% vs. 1.6%; p = 0.0035). Thus, similar to the FRISC-I trial findings with dalteparin, treatment with nadroparin for 6 days provides similar efficacy and safety to treatment with UFH for the same period. A prolonged regimen of nadroparin (14 days) does not provide any additional clinical benefit and is associated with an increase risk of major hemorrhage.

The use of LMWH as an adjunct to fibrinolytic therapy is actively under investi­gation (33-37). Preliminary results from the HART-II angiographic study (37) demonstrated slightly higher rates of infarct artery patency (80.1% vs. 75.1%; p = NS) and TIMI grade 3 flow rates (52.9% vs. 47.6%; p = NS) at 90 min among 200 patients receiving tPA and enoxaparin (30 mg IV bolus followed by 1 mg/ kg SQ twice daily for >72 h) compared to tPA and UFH. Clinical event rates were similar and reocclusion among patients with a patent artery at 90 min tended to be less frequent in those randomized to enoxaparin (5.9 vs. 9.8%; p = NS). In another angiographic study (36), dalteparin was compared with placebo in patients receiving streptokinase. TIMI grade 3 flow 20 to 28 h later tended to be higher in patients treated with dalteparin (68% vs. 51%; p = 0.10) and the number of ischemic episodes on continuous ECG monitoring was lower (16% vs. 38%; p = 0.04).

Loryna Class Action News: News and Information from related Sources

Loryna Class Action: Direct thrombin inhibitors, as indicated by the class name, do not require anti­thrombin or another cofactor to inhibit the function of thrombin. Direct thrombin inhibitors inhibit all the major actions of thrombin, including thrombin-induced generation of fibrin, thrombin-induced platelet activation, as well as thrombin’s autocatalytic reaction. Potential advantages of direct thrombin inhibitors over heparin include: inhibition of clot-bound thrombin lack of inhi­bition by activated platelets; and stable anticoagulant response since no cofactor is required. The prototypic direct thrombin inhibitor is hirudin, a polypeptide consisting of 65 amino acids derived from the leech Hirudo medicinalis. Hirudin selec­tively binds thrombin in a 1:1 fashion at two locations: the carboxy terminus of hirudin binds to the substrate recognition site, the domain of thrombin that recognizes fibrinogen or the platelet and the amino terminus of hirudin binds to the catalytic site of thrombin. Hirudin does not inhibit factor Xa, IX, kallikrein, activated protein C, plasmin, tissue plasminogen activator, or other enzymes in the coagulation or fibrinolytic pathways. Although hirudin does not bind covalently to thrombin, the dissociation rate is extremely slow; thus, hirudin essentially irreversibly inhibits thrombin.

Lepirudin was compared to heparin in the OASIS-2 trial (56). While there were trends toward a reduction in cardiovascular death or MI at 72 h (2.0% vs. 2.6%; p = 0.04) and at 7 days (3.6% vs. 4.2%;p = 0.08), there was an attenuation of this benefit by day 35, in contrast to the sustained superiority of enoxaparin over UFH (30). Furthermore, major bleeding requiring transfusion was more fre­quent with lepirudin (1.2% vs. 0.7% for heparin; p = 0.01). The authors per­formed a metanalysis of all the hirudin trials and observed a modest 10% benefit favoring hirudin, although this was not statistically significant for patients with unstable angina/non-ST-elevation MI at 35 days. The Food and Drug Ad­ministration (FDA) recently reviewed the available clinical data and did not ap­prove hirudin for use in unstable angina/non-ST-elevation MI, citing the lack of sustained benefit and increased risk of bleeding.

In the HIT-3 trial, excess intracranial hemorrhage was observed with lepirudin (0.4 mg/kg bolus, 0.15 mg/kg/h infusion) compared to UFH (3.4% vs. 0%) among 302 patients receiving tPA. In the subsequent HIT-4 trial (71), involv­ing 1208 patients and using a lower dose of lepirudin (0.2 mg/kg bolus, 0.5 mg/ kg subcutaneously b.i.d.) in combination with streptokinase, TIMI flow grade 3 was observed in 40.7% in the lepirudin and in 33.5% in the heparin group (p = 0.16). No difference were seen between lepirudin and heparin in the rate of hemorrhagic stroke (0.2% vs. 0.3%), reinfarction (4.6% vs. 5.1%), or mortality (6.8% vs. 6.4%) at 30 days. Thus, intravenous lepirudin (as administered in HIT- 3) as an adjunct to tPA appears to be unsafe, and lower dose lepirudin in combina­tion with streptokinase does not significantly improve reperfusion or clinical out­comes.

Angiographic trials with other direct thrombin inhibitors in conjunction with fibrinolytic therapy have also been conducted. In a pilot study and the HERO trial, a trend toward improved early (90 to 120 min) TIMI grade 3 flow was observed with the higher dose of Hirulog as compared with heparin in patients receiving streptokinase. Testing with other agents found modest or no improvements compared with heparin. HERO-II, an international phase III trial of approximately 17,000 patients with ST-elevation MI treated with strep­tokinase, is randomizing patients to either Hirulog or UFH and should complete enrollment in the latter half of 2000.

Loryna Class Action News: Information and News

Loryna Class Action: Despite tremendous initial enthusiasm for the direct thrombin inhibitors, their current role in clinical practice is limited to use as an anticoagulant in patients with heparin allergy, or in the treatment of heparin-induced thrombocytopenia and thrombotic syndrome. Ongoing and future research, particularly as adjunctive therapy in patients receiving fibrinolysis or percutaneous coronary intervention, may identify other clinical situations in which these drugs could play a useful role. However, studies to date have identified a narrow therapeutic window, mar­ginal evidence of incremental, sustained efficacy over UFH, and the possibility of a ‘‘rebound’’ effect. These problems represent challenges to this class of anti­thrombotic drugs.

Because approximately 4 million patients each year are admitted to hospitals worldwide with unstable angina or acute myocardial infarction (MI), and nearly 1 million patients annually worldwide undergo percutaneous coronary intervention (PCI), physicians have focused a great deal of attention on developing new treat­ments for these acute coronary syndromes (ACS). The initiating event of these acute coronary syndromes is rupture of an atherosclerotic plaque followed by local thrombosis. Similar pathophysiology is present during PCI, which is essen­tially a ‘‘planned’’ plaque disruption.

The peptide and peptidomimetic inhibitors (e.g., tirofiban and eptifibatide) are competitive inhibitors of the IIb/IIIa receptor, with very rapid half-lives of dissociation from the IIb/IIIa receptor (10-20 s). Thus, the level of plate­let inhibition is directly related to the drug level in the blood. Since both inhibitors have short half-lives, when the drug infusion is stopped the antiplatelet activity reverses after a few hours, which is a potential benefit for avoiding bleed­ing complications. The third group of GP IIb/IIIa inhibitors are the oral agents. Within this group, there are also the two broad types of agents, those that are competitive inhibitors, and those that bind tightly to the receptor. The oral drugs are usually prodrugs, which are absorbed and then converted to active compounds in the blood. The oral agents all have longer half-lives, such that they can be given once, twice, or three times daily in order to achieve relatively steady levels of IIb/IIIa inhibition.

Abciximab was also found to be beneficial when started 24 h prior to a PCI in the c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) trial: death, MI, or urgent revascularization was reduced by abcix­imab from 15.9 to 11.3% (p = 0.012) (27). In the Evaluation of IIb/IIIa inhib­itor for Stenting (EPISTENT) trial (28), compared with stenting with only aspirin and heparin, the rate of death, MI, or urgent revascularization at 30 days was significantly reduced in both abciximab groups—from 10.8 to 5.3% for stent plus abciximab (p < 0.001) and 6.9% for balloon angioplasty with abciximab (p = 0.007) (28). Benefits were maintained at 6 month and 1 year, with a significant reduction in 1 year mortality in patients treated with stent plus abcix- imab compared with stent alone. In addition, a metanalysis of abciximab trials has shown that there is a significant reduction in mortality when GP IIb/ IIIa inhibition is used.

Our use of the term or terms Loryna Class Action News is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Class Action News visit our site often.

Loryna Class Action

Loryna Lawyer News: Please contact us today if you took Loryna and suffered unusual side effects or other injuries.

Loryna Lawsuit: Clinical evidence demonstrating anti-inflammatory and plaque-stabilizing effects of statin drugs has only recently become available. The first study to address whether patients with evidence of inflammation benefited from statin therapy was performed within the Cholesterol and Recurrent Events (CARE) trial, a secondary-prevention evaluation of pravastatin. Consistent with studies of primary prevention, participants in the CARE trial with elevated CRP levels were found to have higher risks of recurrent coronary events than those with lower levels of CRP. However, a clinically apparent interaction between statin therapy and inflammation was also observed in that the proportion of recurrent events prevented by pravastatin was 54% among those with inflammation com­pared with 25% among those without inflammation. Moreover, long-term therapy with pravastatin significantly reduced plasma levels of CRP in a manner that was not related to this agent’s effects on LDL cholesterol. In fact, in this hypothesis-generating study, there was no relationship between the change in CRP and the change in LDL cholesterol at the end of the 5-year follow-up period. Thus, these initial data provided clinical evidence that statin therapy may well have anti-inflammatory properties. While the mechanism of this effect is uncertain, the CARE data provide evidence for possible clinical relevance of laboratory observations demonstrating nonlipid effects of the HMG-CoA reductase inhibitors, such as modulation of immune function, antiproliferative effects on vascular smooth muscle, and antithrombotic properties, as well as morphological ef­fects.

Two major studies have now addressed the validity and clinical importance of these observations. The first, the Pravastatin Inflammation/CRP Evaluation (PRINCE) trial, was explicitly designed to address three questions. First, can the effects of pravastatin on CRP observed in the CARE trial be confirmed in a direct hypothesis-testing setting? Second, how quickly does any effect of pravastatin on CRP occur and are the effects of pravastatin on CRP truly inde­pendent of changes in LDLC? And third, are the effects of pravastatin on CRP observed in CARE (a secondary-prevention study) equally present in primary- prevention populations? In total, the PRINCE trial evaluated 2884 patients: 1182 in a secondary- prevention cohort who received pravastatin 40 mg daily, and 1702 in a primary- prevention cohort randomly allocated to either pravastatin 40 mg daily or placebo. Prior use of lipid-lowering therapy within the previous 6 months was not allowed, and those in the primary-prevention arm had to have LDL choles­terol levels greater than 130 mg/dL. Blood samples were collected at baseline.

As ensured by the randomization process, baseline levels of CRP (median 0.20 mg/dL), total cholesterol (231 mg/dL), LDL cholesterol (143 mg/dL), and HDL cholesterol (40 mg/dL) were virtually identical in the two primary- prevention arms of the PRINCE trial. In contrast, compared with those in the primary-prevention cohort, those with a prior history of cardiovascular disease who were enrolled in the secondary-prevention cohort of PRINCE had signifi­cantly increased CRP levels (median 0.26 mg/dL). As would be expected, those in the secondary-prevention cohort were also older and more likely to smoke or have diabetes, and the group had a higher proportion of aspirin users than the primary-prevention cohort. During the course of the study, highly significant re­ductions in total cholesterol, LDL cholesterol, and triglycerides were observed in the pravastatin groups, as was a clinically important increase in HDL choles­terol (all p values <0.001). No change was observed in any of these parameters among those allocated to placebo.

Loryna Lawyer News: More information about your search

Loryna Lawyer: The main analyses of PRINCE were the effects of statin therapy at both 12 and 24 weeks. In the primary-prevention cohort, pravastatin reduced median CRP levels by 16.9% compared with placebo at the end of the 24-week study period (p < 0.001). This effect was present at 12 weeks (median reduction in CRP with pravastatin 14.7%; p < 0.001). As shown in Figure 7, these effects were observed in all the PRINCE prespecified subgroups, including analyses stratified by age, smoking status, gender, obesity, and lipid levels. As had been hypothesized, virtually no association was observed between CRP and lipid levels either at the study beginning or during follow-up. In fact, in correlational analy­ses, less than 2% of the variance in the change in CRP could be explained by the change in any lipid parameter. Virtually identical effects were also seen in those in the secondary-prevention cohort of the study.

Several decades ago, homocystinuria, a rare pediatric condition, was noted to be associated with musculoskeletal abnormalities and the development of ven­ous thromboembolism and arterial disease in adolescence. The underlying metabolic defect for this condition was shown to be decreased enzymatic activ­ity of cystathionine beta-synthase. This deficiency was associated with in­creased levels of methionine and homocysteine and a decrease in blood levels of cysteine. Later investigations of a patient with elevated homocysteine levels and similar clinical findings, but with a low concentration of methionine in the plasma and evidence of abnormal vitamin B₁₂ metabolism, led to the conclusion that another defect could account for elevated homocysteine levels and vascular disease.

A large variety of factors have been associated with increased levels of homocys­teine, and only the key topics in healthy outpatients will be considered here. Fasting blood homocysteine concentrations are typically greater in the elderly compared with middle-aged adults, and higher in men than in women. Analyses of the Framingham Heart Study and the National Health and Nutrition Examination Survey data have shown that the prevalence of elevated homocyste­ine (>14 |j.mol/L) increases with age in both sexes, and plasma homocysteine levels are inversely correlated with vitamin intake. Vitamins Bj, B₂, B₆, B₁₂, folate, niacin, retinol, vitamin C, and vitamin E have all been studied, but the greatest interest has been shown for vitamins B₆, B₁₂, and folate, as these nutrients act as cofactors for several homocysteine metabolic pathways.

Low vitamin B₁₂ status can also account for elevated homocysteine levels, as this vitamin is a necessary cofactor in several homocysteine metabolic steps. Inadequate production of intrinsic factor in the stomach can result in a severe vitamin B₁₂ deficiency, with substantially elevated homocysteine concentrations, but this etiology is an infrequent cause of low vitamin B₁₂ status. Hypochlorhydria and achlorhydria are more common than inadequate intrinsic factor deficiency, especially in older individuals, and can lead to impaired absorption of vitamin B₁₂ because low pH is needed to dissociate B₁₂ from food.

Loryna Lawyer News: News and Information

Loryna Lawyer: There are many genetic causes of elevated homocysteine levels. Enzymatic de­fects and variants have been associated with cystathionine beta-synthetase, meth­ylene tetrahydrofolate reductase (MTHFR), thermolabile and nonthermolabile variants, and methionine synthetase, to name a few. The MTHFR variant 677- C ^ T has gotten the most attention, as it is relatively common and affects 10 to 15% of North Americans and 5 to 25% of Europeans. This MTHFR variant has also been studied for associations with cardiovascular disease, and homo­zygosity has generally been associated with an increased occurrence of disease; however, several studies demonstrated no association between the MTHFR and vascular outcomes. A meta-analysis concluded that a modest association with increased risk for cardiovascular disease was present. The inconsistent asso­ciation between MTHFR variants and vascular disease may be partially explained by population dietary data. Persons homozygous for MTHFR 677-C ^ T and who had suboptimal folate status were especially likely to have elevated homo­cysteine levels.

Other studies have not always corroborated these results. In some instances, the associations with adverse outcomes were demonstrated for nutrient status, but not for homocysteine levels. For instance, higher homocysteine levels were not associated with greater risk in a MRFIT-nested case-control analysis (20); the ARIC study demonstrated higher folate and B₆ intake to be associated with lower CVD risk but associations with higher homocysteine were not significant (21); and the Nurses’ Health Study investigators found that higher folate and B₆ intake was associated with lower cardiovascular risk. Elevated homocysteine concentrations in the plasma may potentiate thrombin generation and may have relevance in the setting of acute coronary syndromes. A study of approximately 100 persons with acute coronary syndromes was found to have positive associa­tions with F1 + 2 and Factor Vila levels. It has been proposed that hyperho- mocysteinemia potentiates a procoagulant state that may adversely affect the en­dothelium and enhance tissue factor activity.

Large-scale interventional data that reduce homocysteine levels and dem­onstrate favorable effects on cardiovascular risk are lacking, but vitamin supple­ments are being included in a variety of ongoing studies and the results should be forthcoming. The minimal daily dose of folic acid that appears to have maximal efficacy to decrease plasma homocysteine is estimated as 0.4 ^g/day, with higher doses not generally being more effective. It is recommended that vitamin B₁₂ deficiency be ruled out prior to initiating folic acid therapy. Alterna­tively, persons on folic acid therapy can be supplemented with a dose of 400 to 1000 |J.g/day of vitamin B₁₂. The dose of vitamin B₆ recommended was 25 to 50 mg/day and there is little risk of developing complications such as sensory neuropathy at this supplement level.

Loryna Lawyer News: Additional Info and News

Loryna Lawyer: New factors associated with increased risk for coronary heart disease arouse great interest and enthusiasm, kindling the hope that we may enhance identification of individuals at risk for CHD. Important concerns are that such metabolic factors be biologically plausible, measurable, repeatable, strong, graded, and treatable (37-39). Measurement issues include accuracy and precision for the factor in the laboratory and evidence of low or modest variability in the clinical setting. If the laboratory or biological variability is very large, the utility of the measurement for predictive purposes is seriously reduced. Many years of experience and stan­dardization of measurements are available for some vascular risk factors, and less experience is available for homocysteine. New risk factors may provide clues to pathogenesis and in some instances may improve our ability to predict disease. The ability to predict new vascular disease events should be demonstrated after consideration of the core set of factors that are currently available, including age, sex, blood pressure, cholesterol or LDL cholesterol, HDL cholesterol, smoking, and diabetes mellitus. This criterion is often not met in new investigations and considerable experience and relatively large data sets and follow-up may be nec­essary to assure that new factors, such as homocysteine, prove useful in predicting vascular disease risk.

Elevated homocysteine levels may be accompanied by decreased blood levels and intake of folate, vitamin B₆, or vitamin B₁₂. These vitamins are important cofactors in the metabolism of homocysteine, and border­line deficiencies are relatively common, affecting approximately 30% of the el­derly participants in the Framingham Heart Study. Greater intake of these vitamins in the diet, with supplements in the form of multivitamins, or through fortification of foods, has led to less vitamin deficiency and a decrease in the prevalence of elevated homocysteine levels. Fortification of the food supply in the United States with folate was announced in early 1996 with a mandated enactment date of January 1, 1998. Analyses of homocysteine and folate levels before and after fortification have been undertaken in Framingham Heart Study participants and showed a dramatic decline in the prevalence of low folate levels, a reduction in the prevalence of elevated homocysteine from approximately 20 to 10%, and a modest decrease in mean homocysteine levels from approximately 10 to 9 |J.mol/L.

Lupus anticoagulants or nonspecific inhibitors interfere with the assembly of procoagulant complexes. In vitro, these antibodies are associated with the pro­longation of phospholipid-dependent blood-clotting times. Characteristically, clotting times return to normal with the addition of exogenous phospholipid. Lu­pus anticoagulants may demonstrate specificity for blood-clotting proteins, in particular prothrombin. However, the mechanism by which they promote throm­bosis is unknown. Lupus anticoagulants are likely associated with a high risk of first and recurrent thrombosis as well as recurrent pregnancy loss.

LAC are a heterogeneous group of autoantibodies, which prolong the clot­ting time in a variety of assays and may demonstrate specificity for beta- 2 glycoprotein-1. LAC do not prolong clotting times in assays in which phospholipid is present in excess. This suggests that LAC inhibit in vitro coagula­tion by interfering with the assembly of procoagulant complexes on phospholipid surfaces. This observation also forms the basis for the test for LAC—a prolonged clotting time, in a phospholipid-limited assay system, that normalizes with the addition of excess phospholipid confirms the presence of LAC. Anecdotal experi­ence suggests that lupus anticoagulants are much less common than anticardio- lipin antibodies, that they are infrequently transient, and that they are associated with a high risk of complications, although none of these observations has been adequately studied. Furthermore, laboratory assays for lupus anticoagulants.­

Our use of the term or terms Loryna Lawyer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Lawyer visit our site often.

Loryna Lawyer

Loryna Litigation News – 2/16/2012: If you were prescribed Loryna and have suffered negative side effects, please contact us today so that we can put you in touch with an attorney to advise you of your legal rights.

Loryna Litigation: Two recent large trials have studied the efficacy and safety of aspirin in patients with acute ischemic strokes. The International Stroke Trial ran­domized 19,435 patients with acute ischemic stroke to unfractionated heparin, either 5,000 or 12,500 units twice daily, aspirin 300 mg daily, or both heparin and aspirin (11). Among the patients treated with aspirin, there were 2.8% recurrent ischemic strokes within 14 days, compared to 3.9% in the groups not receiving aspirin, and no excess of hemorrhagic strokes. There was a nonsignificant trend for decreased mortality in patients treated with aspirin compared to those not treated with aspirin at 14 days (9% vs. 9.4%). At 14 days, therefore, there was a significant reduction in death or any nonfatal recurrent stroke in the aspirin- treated group (11.3% vs. 12.4%). In patients treated with heparin, there were 2.9% recurrent ischemic strokes within 14 days compared to 3.8% in the groups not receiving heparin, but an increase in hemorrhagic strokes (1.2% vs. 0.4%). As a consequence, there was no significant difference in the incidence of nonfatal recurrent stroke or death between the heparin and nonheparin groups (11.7% vs. 12%, respectively).

Several trials have studied the efficacy of aspirin as primary prevention for myo­cardial infarction, stroke, and death, but the results have not been consistent. The Physicians’ Health Study compared aspirin to placebo in 22,071 male physicians over the age of 40 and followed them for 5 years. Myocardial infarction occurred in 139 persons assigned to aspirin and 239 assigned to placebo. Thus, aspirin was associated with a 44% reduction in the risk of myocardial infarction. Cardiovascular death occurred in 81 persons assigned to aspirin and 83 assigned to placebo. Thus, there was no significant reduction in total cardiovascular mor­tality. The reduction in the risk of myocardial infarction occurred only among men 50 years of age and older. There was a nonsignificant, slightly increased risk of stroke among those taking aspirin compared to those taking placebo. A separate study of 5139 healthy British male physicians compared aspirin to pla­cebo. Total mortality was slightly, but not significantly, less in the control group compared to the aspirin-treated group. There was no significant difference in the incidence of nonfatal myocardial infarction or stroke.

Another British trial, the Thrombosis Prevention Trial, evaluated the effect of low-dose aspirin (75 mg/day) as well as oral anticoagulation with warfarin (average INR = 1.47) in 5499 healthy men aged 45 to 69 years who were random­ized to warfarin, aspirin, both, or neither. The average International Normal­ized Ratio (INR) for those receiving warfarin was 1.47. Warfarin was associated with a 21% reduction in coronary death, fatal, and nonfatal myocardial infarction, and aspirin was associated with a 20% reduction in coronary death and myocar­dial infarction. The risk of hemorrhagic and fatal strokes was increased in the warfarin-treated patients. The principal effect of aspirin was primarily a 32% reduction in nonfatal myocardial infarction; aspirin did not reduce total cardiovas­cular mortality. The effect of aspirin as primary prevention was also evaluated in 87,678 U.S. registered nurses who had been participating in a prospective cohort study. Among women taking one to six aspirin per week, there was a significant, 32% relative risk reduction for myocardial infarction, a nonsignifi­cant, 11% relative risk reduction for cardiovascular death, and no decrease in the risk of stroke.

An analysis of 21 trials included in the Antiplatelet Trialists’ Collaboration found that the odds ratio among persons using aspirin for upper gastrointestinal bleeding was 1.7; for peptic ulcer, 1.3; and for all gastrointestinal bleeding, 1.5 to 2.0. The risk of cerebral hemorrhage is increased by aspirin. A recent metanal- ysis of 16 trials constituting 55,462 persons found that the absolute risk of hemor­rhagic stroke in groups treated with aspirin was 1.2 per thousand individuals accounting for a relative risk of 1.84. Hypersensitivity reactions to aspirin, including nasal congestion, urticaria, and bronchospasm may occur. The frequency of these adverse effects in patients with chronic urticaria is 23%, in patients with asthma is 4 to 19%, and in patients with nasal polyps is approxi­mately 23%.

Loryna Litigation News: Additional Information and Resources

Loryna Litigation: The Studio della Ticlopidinia nell’Angina Instabile Groupe evaluated the efficacy of ticlopidine in 652 patients with unstable angina. Following treat­ment for 6 months, 7.3% of the patients receiving ticlopidine had a nonfatal myocardial infarction or vascular death compared to 13.6% of patients who did not receive ticlopidine, accounting for a 46.3% relative risk reduction. Several trials have evaluated the efficacy of ticlopidine in preventing throm­bosis or ischemic events subsequent to placement of an intracoronary stent. The Full Anticoagulation versus Aspirin and Ticlopidine (FANTASTIC) study ran­domized patients to aspirin and ticlopidine or to aspirin and conventional antico­agulation with heparin or oral anticoagulants. The primary endpoint of bleed­ing or peripheral vascular complications occurred in 13.5% of patients treated with aspirin and ticlopidine and 21% of patients treated with aspirin and anticoag­ulants. The overall incidence of stent occlusion was similar in each group; yet, acute stent occlusion occurred more frequently in the antiplatelet group (2.4 vs. 0.4%), whereas subacute stent occlusion within 1 week occurred more frequently in the anticoagulant group (3.5 vs. 0.4%).

The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS) study randomized 350 high-risk patients following stent implantation to aspirin and ticlopidine or to aspirin and oral anticoagulation. After 30 days, the primary cardiac endpoint of cardiovascular death, myocardial infarction, or repeated revascularization occurred in 5.6% of the aspirin and ticlopidine group compared to 11% of the aspirin and anticoagulant group, accounting for approximately 50% reduction in the risk of an adverse event with the former compared to the latter group. Schomig et al. randomized 257 patients undergoing placement of coronary artery stents to aspirin and ticlopidine, or to aspirin plus anticoagulation with heparin or phenprocoumon. The primary cardiac endpoint of cardiac death, nonfatal myocardial infarction, coronary artery bypass surgery, or repeat angio­plasty occurred in 1.6% of patients randomized to aspirin plus ticlopidine as compared to 6.2% of those randomized to aspirin plus anticoagulation, account­ing for a relative risk of 0.25 in those randomized to antiplatelet therapy alone. Moreover, hemorrhagic complications occurred in 6.5% of the anticoagulant ther­apy group, but in none of the antiplatelet therapy group.

Two large clinical trials evaluated the efficacy of ticlopidine in patients with symptomatic cerebrovascular disease. The Canadian American Ticlopidine Stud­ies (CATS) randomized 1072 with recent thromboembolic stroke to ticlopidine or placebo and followed them for an average of 24 months. The primary endpoint of stroke, myocardial infarction, or vascular death occurred in 15.3% per year of those treated with placebo and 10.8% per year of those treated with ticlopidine, accounting for a relative risk reduction with ticlopidine of 30.2%. There was no significant difference in the total mortality rate, which was 4.5% per year in those receiving placebo and 4.1% per year in those receiving ticlopidine. The Ticlopidine Aspirin Stroke Study (TASS) randomized 3069 patients with recent transient ischemic attack, amaurosis fugax, or minor stroke to aspirin or ticlopidine.

Several studies have examined the efficacy of ticlopidine in patients with periph­eral arterial disease. Balsano etal. studied 151 patients with intermittent claudica­tion who were randomized to treatment with ticlopidine or placebo. Improve­ment in pain-free and maximal walking distance was greater in the ticlopidine than in the placebo group. The Swedish Ticlopidine Multicenter Study (STIMS) assessed the effect of ticlopidine on cardiovascular events in 687 patients with intermittent claudication followed for a median duration of 5.6 years. The incidence of myocardial infarction, stroke, and transient ischemic attack was 29% in patients treated with placebo compared to 25% among those treated with ticlopidine, accounting for a risk reduction of 11.4% in favor of ticlopidine. Mortality was 26.1% in the placebo group and 18.5% in the ticlopi­dine group, accounting for a relative risk reduction of 29%. A recent metanalysis involving studies of patients with intermittent claudication found that mortality was significantly decreased by ticlopidine compared to placebo, with an odds ratio of 0.68.

Loryna Litigation News: News and Information from related Sources

Loryna Litigation: Several additional trials that are assessing the efficacy of clopidogrel in preventing cardiovascular events are currently taking place. These include: the Clopidogrel Reduction of Events During Extending Observation (CREDO) trial in which patients undergoing percutaneous revascularization will receive clopido­grel with aspirin for 1 year versus clopidogrel plus aspirin for 1 month followed by aspirin for another 11 months and the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial in which patients with congestive heart failure will be randomized to warfarin (titrated to an INR of 2.5-3.0), clopidogrel 75 mg/day, or aspirin 160 mg/day, and followed for up to 5 years.

In the CAPRIE trial, bleeding occurred with comparable frequency in the patients receiving clopidogrel compared to aspirin (9.27% vs. 9.28%, respectively). In patients receiving clopidogrel, intracranial hemorrhage occurred in 0.35% and gastrointestinal hemorrhage in 1.99%, the latter being less frequent than in pa­tients receiving aspirin. In patients receiving clopidogrel, diarrhea occurred in 4.46% and rash occurred in 6.02%. Of patients receiving clopidogrel, neutro­penia (<1200/|J.L) was present in 0.1%, severe neutropenia (<450/|J.L) in 0.05%, thrombocytopenia (<100 X 10³/|J.L) in 0.26%, and severe thrombocytopenia (<80 X 10³/|J.L) in 0.19% of patients receiving clopidogrel. A recent report high­lighted the potential association of thrombotic thrombocytopenic purpura with clopidogrel (41). Eleven patients who had been treated with clopidogrel, 10 of whom had been treated for 14 days or less, were identified over a 2-year period by active surveillance of medical directors of blood banks, hematologists, and a surveillance overseen by pharmaceutical manufacturers. At the time of this report, the authors estimated that more than 3 million people had received clopidogrel. Idiopathic thrombotic thrombocytopenic purpura has been estimated to occur in approximately 3.7 per million.

Heart failure was the first major area in which ACE inhibitors have proven their undisputed role in improving clinical outcomes, indeed, survival. In the early 1980s, the ‘‘vasodilator era,’’ then pioneering acute studies revealed that favor­able hemodynamic improvements could be obtained by ACE inhibitors in patients with severe heart failure. The first demonstration of a survival benefit with the use of an ACE inhibitor in any cohort of patients can be attributed to the Cooperative North Scandinavian ENalapril SUrvival Study (CONSENSUS), which randomized patients with severe heart failure. In this trial, despite the use of digitalis, diuretics, and other vasodilators, the placebo mortality rate was exceedingly high, approaching 50% at 6 months. Those randomized to the active therapy (enalapril) had a pronounced reduction in the risk of death. Indeed, the combination of the high placebo event rate and the relative effectiveness of ther­apy led to conclusive results in a population of approximately 500 patients.

The Studies of Left Ventricular Dysfunction (SOLVD) greatly expanded the indications for ACE inhibitors as a consequence of their results in two parallel randomized trials collectively involving over 6000 patients. In the treatment arm, symptomatic heart failure patients with left ventricular dysfunction (ejection fraction <35%) of all etiologies were randomized to placebo or enalapril. Despite background therapy with digitalis or diuretics or both, the enalapril group experi­enced a 16% reduction in the risk of death and clear reductions in the need for rehospitalization for heart failure. The same screening procedures identified and randomized over 4000 patients who also had left ventricular dysfunction. However, the study investigators did not feel that these patients had sufficient symptoms to warrant therapy—the Prevention Arm. In this unique group, the randomization to enalapril showed a favorable trend for a reduction in fatal events with a clear reduction in the development of heart failure during the ap­proximately 4 years of follow-up. As a consequence of these and other smaller studies, ACE inhibitors had proven themselves as an essential, indeed, ‘‘corner­stone’’ therapy for the management of patients with heart failure. In some respects, the V-HeFT-II study put the icing on the cake for the use of ACE inhibi­tors in heart failure. It showed that, in a group of symptomatic heart failure pa­tients randomized to either the combination of hydralazine and nitrates (the first life-sustaining therapy for heart failure) versus enalapril, the ACE inhibitor re­sulted in superior survival even compared to a previously proven therapy for heart failure. Taken together, we now had clear evidence that the morbidity and mortality of heart failure could be effectively reduced by the use of an ACE inhibitor.

Loryna Litigation News: Information and News

Loryna Litigation: The rationale for the treatment of patients with myocardial infarction with an ACE inhibitor stems from the pioneering work of the late Dr. Janice Pfeffer, beginning when she was a fellow in the Braunwald laboratory. Experimental models of infarctions were readily utilized to determine whether infarct size could be favorably modified by pharmacological therapy. Pfeffer explored the relation­ship between infarct size and ventricular function and incorporated important lessons from her doctoral training in hypertension at Edward Frohlich’s labora­tory to determine the long-term consequences of abrupt loss of myocardium from coronary ligation. Indeed, she demonstrated in the animal model that the loss of myocytes should be viewed as the beginning of an insidious phase of progressive ventricular enlargement (remodeling), which is related both to the extent of the histological damage as well as to the duration of time from the infarct. In­deed, the enlargement itself is a central component in the progressive worsening of dysfunction. Ventricular remodeling could also involve the normal remaining myocardium, which, as a consequence of unfavorable geometry and wall stress, could suffer an abnormal hemodynamic burden.

These observations of ventricular remodeling provided a new therapeutic target for a novel use of ACE inhibition—to attenuate time-dependent ventricular enlargement following infarction. The use of ACE inhibitors was a natural exten­sion of her work in hypertension, where these agents were particularly effective in preventing hypertrophy and left ventricular chamber enlargement. In the myocardial infarction model, long-term administration of an ACE inhibitor did indeed attenuate ventricular enlargement as treated animals had smaller left ven­tricular cavities and more preserved ventricular pump function. In a subse­quent study, a prolongation of survival was demonstrated with ACE inhibitor treatment.

These animal studies provided the rationale for initially small mechanistic studies, which confirmed both the process of progressive enlargement post-myo­cardial infarction and the attenuation of enlargement with the use of an ACE inhibitor. These mechanistic studies were soon followed by an extensive series of international multicenter randomized trials testing the hypothesis that administration of an ACE inhibitor to patients in the acute and chronic phases of myocardial infarction would lead to improved survival. The Survival and Ven­tricular Enlargement (SAVE) study, as suggested by the trial’s acronym, tested the hypothesis that attenuation of ventricular enlargement in high-risk patients post-myocardial infarction would lead to improved survival. The SAVE study demonstrated that the addition of captopril to a conventionally treated pa­tient who survived a myocardial infarction with an ejection fraction less than 40% without overt heart failure would lead not only to a reduction in the risk of death, but also to a reduced risk of developing heart failure and experiencing a recurrent myocardial infarction. A detailed quantitative echocardiographic study did confirm an attenuation in remodeling in the ACE inhibitor group and, more­over, these investigators were able to demonstrate linkage between progressive enlargement, risk of an adverse cardiovascular event, and the favorable benefit of the ACE inhibitor therapy.

The Acute Infarction Ramipril Efficacy (AIRE) study administered the ACE inhibitor ramipril to patients starting in the acute phase of the infarct and continuing long term. The AIRE investigators identified high-risk patients based on clinical signs or symptoms of pulmonary congestion or transient heart failure. The long-term administration of the ACE inhibitor resulted in a 26% reduction in the risk of death and comparable reductions in other nonfatal cardiovascular endpoints. The TRandolapril Cardiac Evaluation (TRACE) investigators employed echocardiographic assessment of wall motion to identify higher risk acute infarct patients. Here, again, the randomization to the ACE inhibitor resulted in an im­portant reduction in the risk of death. In the Survival of Myocardial In­farction Long-term Evaluation (SMILE), the ACE inhibitor zofenopril was ad­ministered to patients with anterior myocardial infarction who had not received thrombolytic therapy. This randomized trial demonstrated a reduction in risk of death or development of heart failure during only 6 weeks of therapy. The TRACE and AIRE investigators have extended their observations beyond the formal trial period and demonstrated that the survival benefits persisted.

Our use of the term or terms Loryna Litigation is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Litigation News visit our site often.

Loryna Litigation

Loryna Settlement News – 2/16/2012: If you were prescribed Loryna and have suffered negative side effects, please contact us today so that we can put you in touch with an attorney to advise you of your legal rights.

Loryna Settlement: An overview of this selective approach to the use of ACE inhibitors for higher risk myocardial infarction patients indicates that approximately 20 to 30 lives are saved in the first month of treatment and that, with continued therapy, approximately 60 to 80 lives are saved per 1000 patients treated. It is impor­tant to underscore that the benefits of the use of an ACE inhibitor in myocardial infarct patients could be considered as additive to conventional therapy with thrombolytics, beta-blockade, and even aspirin. Therefore, it is fair to conclude that use of an ACE inhibitor in these patient populations results in a new and complementary modality to reduce risk of death and other major cardiovascular events.

The only ‘‘fly in the ointment’’ in the field of ACE inhibitors and acute myocardial infarction was from the CONSENSUS II study, which showed a nega­tive trend when ACE inhibitor therapy was started intravenously in the first day of the infarct and then continued orally for the projected study duration of 6 months. With over 100,000 patients in randomized, placebo-controlled trials of different designs, agents and durations, the consensus of international experts strongly recommends the use of an ACE inhibitor starting early and continued long term for patients at higher risk. These authoritative guidelines do indi­cate that there are sufficient rationale and data for clinicians to adopt a more global approach for the use of ACE inhibitors in an even broader population.

Additional mechanisms to explain the ACE inhibitor influence on coronary events soon came from novel experimental studies that revealed an important interface between the renin-angiotensin system and the balance between throm­bolysis and thrombosis. An infusion of angiotensin-II raised plasminogen activa­tor inhibitor-1 (PAI-1), which would alter the fibrinolytic balance toward throm­bosis. The randomized use of ACE inhibitors in patients with acute myocardial infarction did indeed lower PAI-1 levels and, particularly, the balance of PAI-1 to intrinsic tPA. Augmented PAI-1 levels had been associated with greater risk of infarct and others had speculated that reduced PAI-1 may be an indication of restoration of endothelial function. In the TREND study, the long-term treatment with the ACE inhibitor quinipril led to a better restoration of coronary endothelial function. Along these lines, it has been postulated that lowering angiotensin-II with an ACE inhibitor would reduce superoxide anions, promote nitric oxide, and limit further vascular damage.

In the mid-to-late 1990s, three major trials were initiated to determine whether an ACE inhibitor would reduce atherosclerotic events. The Heart Out­comes Prevention Evaluation (HOPE) study selected patients for clinical evi­dence of vascular disease with prior myocardial infarction, stroke, peripheral vas­cular disease, or diabetes plus another risk factor and randomized to conventional therapy plus placebo or ramipril. Patients with heart failure or known depressed ejection fraction were excluded. The Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) study, specifically designed as a follow- up of SAVE, included patients with documented coronary disease and an ejection fraction over 40% randomized to conventional therapy plus either trandolapril or placebo. The EUropean trial on Reduction Of cardiac events with Perindo­pril in stable coronary Artery disease (EUROPA) randomized patients with coro­nary disease regardless of their ejection fraction to either perindopril or placebo.

Loryna Settlement News: Additional Information and Resources

Loryna Settlement: HOPE was the first of these major studies to be completed. Randomization to ramipril resulted in a convincingly consistent 20% and greater reduction in ath­erosclerotic events, such as cardiovascular death, myocardial infarction, and stroke. The HOPE study results are based on a substantial number of clinical events and consistent findings were present in all predefined subgroups. Again, the small reduction in blood pressure with the ACE inhibitor in and of itself could not explain the magnitude of the clinical benefits in this patient population. Within the HOPE study, a mechanistic trial evaluating carotid arterial thickness as a surrogate marker of the atherosclerotic process did demonstrate a dose-dependent reduction in ca­rotid thickness with the use of an ACE inhibitor. Other important mechanistic observations such as the reduction in the development of diabetes and diabetic complications may provide additional key insights. Indeed, the hemoglobin A1C levels in the subpopulation evaluated was reduced by chronic therapy with the ACE inhibitor. The HOPE study expands both the patient population who will receive benefits from ACE inhibitor therapy as well as the potential mechanisms that can be evoked to explain these impressive beneficial actions.

With the obvious broad overlap in patients who would benefit from both of these agents, a negative interaction with the concomitant use of these two agents would have major public health implications. At the outset, it must be acknowledged that there is yet to be a two- by-two trial of aspirin and ACE inhibitors as there was of thrombolytics and aspirin in ISIS-2. Indeed, with the now established benefits of both of these agents, such a trial in which patients would have either of these life-saving thera­pies withheld would be deemed unethical. Decisions will have to be based on the experience of prior trials. Since most of the major aspirin trials were con­ducted prior to the knowledge of the survival benefit of ACE inhibitors, there are few data on concomitant use. On the other hand, there is extensive experience in the ACE inhibitor trials with patients on aspirin.

The initial hypothetical question of a possible interaction, whereby the con­comitant use of both drugs offsets the potential benefits of an ACE inhibitor, was proposed by Donald Hall and his colleagues. A mechanistic study of patients with severe heart failure and marked neurohormone activation observed that the vasodilating effect of enalapril was offset by the concomitant use of aspirin. Since one of the important actions of an ACE inhibitor, aside from reducing the production of angiotensin-II, is to impede the breakdown of bradykinin, which also enhances the production of prostaglandins, it was reasoned that an aspirin effect on inhibiting prostaglandin synthesis could offset some of the hemody­namic benefits of administering an ACE inhibitor. Indeed, their work on the he­modynamics of severe heart failure was confirmed by others. This is similar to the use of nonsteroidal anti-inflammatory agents that had long been known to exacerbate signs and symptoms of heart failure, impairing renal function, and even offsetting antihypertensive effects of a variety of therapeutic compounds. Hall provided mechanistic underpinning and focus for important questions regarding a potential for aspirin to offset some of the clinical benefits of ACE inhibitor use in patients with severe heart failure.

Subsequently, a subgroup analysis from the SOLVD studies did indicate that there was a trend for less of a survival benefit in patients randomized to the ACE inhibitor who were reported to be on aspirin at baseline. Proponents of an important negative interaction whereby aspirin offsets some of the benefits of an ACE inhibitor could also turn to the CONSENSUS-II acute myocardial infarction study to bolster these positions. Conversely, subgroup analyses from other large studies appear to refute these observations. With the proven benefits of both of these agents independently and the overlapping clinical profile of pa­tients that should be receiving these therapies simultaneously, this becomes a critical question to resolve.

Loryna Settlement News: News and Information from related Sources

Loryna Settlement: In the short term, broad-inclusion analysis of 96,712 patients, aspirin was used at baseline in 86,884 (89.4%) and not in 10,228 patients (10.6%). Aspirin use was not randomized and, as it turns out, there was a marked disparity in risk profile with respect to use of aspirin. Patients who did not receive aspirin were less likely to receive thrombolytics or beta-blockers, were older, and were more likely to have had pulmonary congestion as is manifested by Killip Class 2 and 3. Not surprisingly, regardless of ACE inhibitor status, the non-aspirin-treated patients had more than twice the mortality rate (14.4 vs. 6.5%, no aspirin vs. aspirin) in these short-term studies. The test for heterogeneity between the reductions in risk of death produced by randomization to the ACE inhibitor in the presence or absence of aspirin use at baseline was not significantly different. This analysis is inclusive of CONSENSUS-II, which is frequently cited as an example of an aspirin-ACE interaction where no benefit of the ACE inhibitor was observed in the presence of aspirin.

Since we have not had (and are unlikely to have) a direct two-by-two test of these two proven agents, interpretation of the information from the existing studies must suffice to generate our clinical conclusions. Along these lines, it is fortunate that use of ACE inhibitors for reduction of cardiovascular events is an extremely well-studied area. Particularly so in patients with myocardial in­farction, with over 100,000 patients in randomized trials and the majority on aspirin, providing a good data set from which to draw these conclusions. Just as the antiplatelet trialists have formed a collaboration to collectively extract more data from their individual studies, so have the ACE inhibitor myocardial infarction investigators. Representatives from eight major trials have pooled their individual data to provide more precise point estimates and to particularly probe prospective subgroup analyses for both efficacy and safety. The ACE Inhibitor Myocardial Infarction Collaborative group prospectively determined that the broad-inclusion, short-term studies should be analyzed separately from the elec- tive-inclusion, long-term studies. Both of these systematic overviews (metanal- ysis) have been completed and recently published.

Symptomatic arterial occlusive disease generally occurs when the artery lumen is reduced to half normal. Atherosclerosis is by far the most common cause of peripheral arterial occlusive disease. Other etiologies must be considered in individuals who do not have risk factors for atherosclerosis or in those who have an unusual distribution of arterial occlusive disease. These etiologies include Ta­kayasu arteritis and giant cell arteritis. Both of these arteritides may result in stenosis of any extremity vessel, visceral vessels, or the aorta. Other forms of vasculitis also result in symptomatic arterial occlusive disease. Thromboangiitis obliterans should be suspected if the distal arteries of the upper and lower extrem­ities are involved, particularly in those who smoke cigarettes. Acute arterial occlusion occurs as a consequence of embolism or thrombosis in situ. Thrombosis can develop acutely in atherosclerotic arteries or it can occur in locations such as the renal arteries in the presence of antithrombin-III deficiency.

Symptomatic lower extremity atherosclerosis is reported in 3% of those individuals over age 50. In individuals greater than 70, over 25% have evi­dence of peripheral arterial occlusive disease by noninvasive testing. The preva­lence of peripheral arterial disease is threefold greater when determined by nonin­vasive testing for arterial stenosis rather than by questionnaires regarding symptoms, consistent with the observation that two-thirds of affected individuals are asymptomatic by traditional history. Yet, in a recent community screening program, these asymptomatic individuals had lower functional capacity than those without peripheral arterial disease, as well as an increased risk of cardiovas­cular death.

Loryna Settlement News: Information and News

Loryna Settlement: Noninvasive testing for lower extremity arterial occlusive disease provides objec­tive information that, together with the history and physical examination, is used to make decisions regarding further evaluation and treatment. These tests can be used for screening, for physiological assessment of hemodynamically signifi­cant stenosis, and to follow-up after revascularization procedures. The most sim­ple and widely used noninvasive test of extremity arterial occlusive disease is measurement of systolic pressure using a sphygmomanometric cuff and a Doppler device to detect arterial flow. Duplex scanning extends the capabilities of nonin­vasive testing by identifying anatomical and physiological information at the sites of arterial stenoses.

Three-dimensional arterial reconstruction using magnetic resonance im­aging (MRI) arteriography and spiral CT arteriography can provide non­invasive assessment of the distal aorta and iliac vessels, but presently with less clarity than is available with invasive arteriography. Contrast arteriography is necessary to completely evaluate the anatomical extent of disease in the distal aorta and lower extremity arteries. It is generally performed only in order to determine the optimal revascularization procedure because of its invasive nature and risk. The functional significance of the arterial occlusive disease can be confirmed by invasive pressure measurements proximal and distal to the stenosis, and can be determined before and after administration of a vasodilator.

The combination of B-mode ultrasound scanning and pulsed Doppler interrogation allows noninvasive assessment of the anatomy and hemodynamic abnormalities in the arterial segments from the distal aorta to the popliteal trifurcation. For exam­ple, soft plaque and thrombi may have similar acoustic properties to blood and, therefore, may not be detected by B-mode imaging, but they will result in a flow disturbance that can be detected by Doppler evaluation. Equipment for peripheral arterial testing includes a linear array transducer, operating at a gray-scale fre­quency of 4 to 10 MHz, and capable of providing frequencies above 3 MHz for Doppler signal analysis. Gray-scale imaging is used to examine the arteries and the presence of detectable atherosclerotic plaque or thrombus. The pulsed Doppler spectral analysis is used to document the presence of blood flow and to determine blood flow velocity. Normal Doppler waveforms in the lower extremity will be triphasic, with a peak velocity less than 120 cm/s. Color Doppler flow mapping allows for a rapid survey of the arteries in order to identify those sites where more labor-intensive and precise Doppler spectral analysis is needed. Still, full evaluation of the lower extremity arteries takes from 1 to 2 h.

Duplex examination can be combined with exercise testing to detect disproportionate velocity increases with exercise and therefore identify the le­sions responsible for a patient’s symptoms. The duplex scan is potentially supe­rior to angiography in the evaluation of iliac artery, and in determining the hemo­dynamic status of ostial lesions in the profunda and superficial femoral arteries. Peripheral artery bypass grafts can be followed serially with duplex ultrasonogra­phy. The first month after surgery and every 1 to 2 years following surgery are key times to identify early changes consistent with stenosis within the graft. The criteria for discrete stenosis in bypass grafts is similar to that in native ves­sels. In addition, a peak systolic velocity that is decreased to 45 cm/s indicates a dramatically increased likelihood of graft failure and provides a rationale for early intervention. In addition, duplex evaluation is likely to be similarly useful in the follow-up of peripheral arteries following percutaneous revascularization.

Our use of the term or terms Loryna Settlement is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Settlement News visit our site often.

Loryna Settlement

Loryna Side Effect News- 2/16/2012: You deserve to be compensated if you took Loryna and suffered side effects that the public was not warned about. Contact us today and we will arrange a free consultation with a lawyer experienced in pharmaceutical and medical device ligation that can advise you of your legal rights.

Loryna Side Effect: Until recently, we only had aspirin, but now a number of new, highly effective medications have been approved to decrease platelet stickiness and prevent the formation of blood clots. The last few years have brought remarkable progress and hope for the stroke survivor. In addition to our good old standby aspirin, the “Grande Dame” of blood clot prevention, we now have multiple medications that also decrease platelet stickiness and clot formation—and go a long way toward preventing anoth­er stroke or vascular death. One has only to turn on the television or open a magazine and you will see advertisements for these medications.

Furthermore, treating a stroke patient’s depression with an­tidepressants also has been found to enhance his physical and cognitive rehabilitation. Each antidepressant has its own side effects, including sleep disturbances, agitation, and sexual dysfunction. Some of the old­er antidepressants interfere with cognition (the ability to “know”) and should be avoided. A clinician must take a patient’s individu­al stroke symptoms into account when determining which medi­cation is best. Our newer antidepressant medications are so effective that frequently the importance of psychology is ignored. However, both medication and counseling are important. Studies have shown that used together the result is superior to either used alone.

When physicians mention the use of a stimulant medication, the first reaction is usually less than enthusiastic. Patients and their families picture children with attention deficit disorders or con­jure up the horrors of amphetamine abuse. But this close-minded thinking may make them miss a very important treatment both in the early and latter phases of stroke rehabilitation. According to experimental evidence, ani­mals treated with amphetamines immediately after their stroke recover to a higher functional level. In other words, stimulants may either have a protective effect on brain cells or assist in their recovery after a stroke. This is still far from common practice in most acute care hospitals, but that can change as more research shows the effectiveness of these medications.

Loryna Side Effect News: More information about your search

Loryna Side Effect: Like their antidepressant cousins, tranquilizers can help decrease the emotional anxiety that accompanies stroke, which, if left un­checked, could sabotage the rehabilitation process. And this anxiety is very real. The fear of a stroke recurring, the fear that it is still in progress, the overwhelming fear of how their lives will change—all these can create irritability, anxiety, and insomnia. Tranquilizers can help ease the pain of these fears, but, as with antidepressants, they must be closely monitored. They can interfere with cognitive abilities. Their use should be “time lim­ited” to avoid dependence. Side effects include drowsiness, dizziness, and possible addiction.

Yes, stroke survivors can have seizures, but they are not common. If someone you love suffers from seizures as a result of stroke, however, there is help. Anticonvulsants usually will control sei­zures. However, regular blood tests will be required to adjust the dosage. The proper levels must be present in blood in order for this medication to work. Too little and it will not be effec­tive against seizures; too much and there is the danger of side effects—which include nausea, drowsiness, balance problems, and liver abnormalities.

Although not a medication, it seemed best to cover this procedure in this chapter. Carotid endarterectomy is an operation that is performed when too much cholesterol has built up in the carotid artery in the neck. Developing the skills to perform this operation has not been as difficult as deciding which patient is an appropriate candidate. Recently, a large study helped identify which patients would ben­efit most; the findings show that determination should be based on how much the carotid artery is narrowed and whether the per­son is currently experiencing any stroke symptoms.

When injured or in pain, we want to go to the best doctor, the best specialist, for our condition. When it comes to dental work or orthodontics, we want to know we are in good hands. Even outside the world of medicine, the best is something we strive for: a restaurant to celebrate a birthday, a vacation in the sun, a car for our family. We want to try, as much as possible, to get the best quality for our money.

Rehabilitation is no exception. There are good rehabilita­tion facilities and there are bad ones—and which you choose can make all the difference in whether or not your loved one gets the care he needs and deserves. And, believe it or not, there are re­habilitation facilities that are better than others—at the same or lower cost. Further, since studies have shown that the average stroke survivor lives an additional seven and a half years, there is no doubt that doing some “rehabilitation detective work” and finding the right facility can have positive results!

Loryna Side Effect News: Additional Information and Resources

Loryna Side Effect: True, there are certain rules, specific guidelines, that thera­pists must follow. Therapists must be trained and educated very carefully. They are required to receive an advanced degree in their specific area, in addition to hands-on work in the field. In short, by the time you see any of the therapists on your rehabilitation team, they have had a great deal of education and experience. But there is more than expertise at work in rehabilitation. Some people have that extra “something,” a talent that school- books cannot supply. A therapist who interacts with you in a way that makes you feel secure, who motivates your loved one to try her very best, who helps and doesn’t hinder—this is a rehabilita­tion therapist worth seeking out. A good facility will have this type of therapist on staff. It should be the unspoken credo of the entire rehabilitation team.

Although the ads you see for nursing homes make them sound like a dream come true for the elderly—more like resorts or rehabilitation facilities than nursing homes—the reality is that they do not always ensure progress, and they may even hinder ul­timate success. Changing a sign on the building from ABC Home for the Aged to ABC Rehabilitation Center doesn’t change the facts. The statistics speak for themselves: studies have found that patients in inpatient rehabilitation hospitals were three times more likely to be discharged home than those who went to nursing homes.

Do stroke patients do as well in a skilled nursing facility as in a true rehabilitation hospital? Are they as likely to be discharged home and back to the care of their loved ones? The answer to both questions: definitely not! And there are scientific studies to prove it. That’s right: three times more likely to sleep in their own bed, eat with their families, and kiss their grandchildren goodnight. Knowing this, where would you or a loved one want to go if you had a stroke?

The goal of a human being is to be independent and to en­joy a life that is as productive and of good quality as possible. A person who has had a serious illness or injury is no excep­tion. Whether it’s as basic as helping a person who has had a stroke learn bladder and bowel routines so that she can maintain some level of independence and dignity, or as complex as aid­ing a person who has lost her memory, rehabilitation works for your loved one, your family, and you. The highest correlation of self-esteem in a person is the ability to control one’s bladder and bowels. Inpatient rehabilitation facilities have entire programs to focus just on this area.

Loryna Side Effect News: News and Information from related Sources

Loryna Side Effect News: Hospital acute care. This is the place you go to immedi­ately after an accident or a stroke. It is the “emergency room of rehabilitation care” where you’ll find an actual emergency room, an intensive care unit, and operating rooms. In an ideal world, rehabilitation starts here. A medical team performs a variety of diagnostic tests that may include a blood workup, x-rays, or brain scans. A respiratory therapist will ensure that lungs are kept clear. Other members of the rehabilitation team will provide proper po­sitioning and movement to prevent bedsores, weakened muscles, or spasticity.

Day program. Think of a day program as the workplace or a school. In this type of rehabilitation program, you will receive all of the usual therapies and medical treatments with a daily “work” day that may last from four to eight hours. At day’s end, the patients return home to sleep, eat, and be with their families. This is the perfect setting for the patient who still needs multiple therapies but is able to return home at night and on the weekends to be with her family. Transitional living. This is exactly as it sounds: a transi­tional residence that is halfway between a rehabilitation hospital and home, sweet home. It is a place for those who have “gradu­ated” from their rehab program, but are not yet ready to reen­ter their community and live at home. In this supervised setting, people work on such skills as menu preparation, group social skills, and behavior management, while continuing their reha­bilitation program.

Rehabilitation does not take place in a vacuum. Work performed on the lower extremities is not done without coordination of speech and other therapies. It is not a question of three weeks for physical therapy, followed by six weeks for speech, and ending with four weeks for relearning such basic skills as using a knife and fork and getting dressed.

The rehabilitation team works together, implementing and reinforcing this interrelated approach. The speech therapist knows the progress a patient is making in language and cogni­tive therapy. The occupational therapist knows where the patient stands in activities of daily living. Each team member works in concert with the others, in communication with the others, even working side by side with the others. This makes sense: as a pa­tient learns to use a wheelchair, he also might be learning how to make change in a supermarket. As he learns to walk from his bed to the bath, he also is learning how to shower and get dressed.

Our use of the term or terms Loryna Side Effect is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Side Effect News visit our site often.

Loryna Side Effects

Both plaintiffs and defendants in asbestos lawsuits agree that asbestoscauses 80 to 90 percent of all mesothelioma cases. You would think that it naturally follows that 80 to 90 percent of mesothelioma lawsuit plaintiffs do not have to prove to a jury that asbestos exposure caused their mesothelioma. Until recently, that was not the case. Instead, through a legal process called reverse bifurcation, most if not all mesothelioma lawsuit plaintiffs had to first prove in court that their mesothelioma diagnosis is tied to past asbestos exposure. Once this was proved – and it usually was — most cases settled out of court.

Now, as reported by the Legal Intelligencer, after nearly a quarter of a century of trying asbestos lawsuits with reverse bifurcation, the Philadelphia Common Pleas Court’s mass torts program for asbestos began “straight-through trials” of asbestos cases in which it is uncontested that plaintiffs have mesothelioma because of asbestos exposure.

“Straight through trial” basically means that the plaintiffs do not first have to prove to the court – with documents and records and other evidence – that asbestos exposure caused their mesothelioma. Instead, the court takes for granted that it did, in which case most lawsuits settle out of court. So far though, even those that have gone through to trial have ended favorably for plaintiffs. One such mesothelioma patient and his family won $4.5 million in a recent trial verdict.

It’s good news for mesothelioma victims and not so good news for some defendants who make or have made asbestos-containing products. Examples of companies that had ready defenses to disprove asbestos exposure from their products as the cause of mesothelioma in a plaintiff include break pad manufacturers and insulation companies. These defendants would use reverse bifurcation to fight off taking responsibility for the victim’s illness. Hopefully, more states will follow PA’s lead on this.

If you or a loved one has suffered from asbestos exposure and later developed mesothelioma, call an asbestos attorney at Sokolove Law today for a free consultation.

Asbestos

A new study financed by a section of the National Institutes of Health has made the first potential connection to an individual’s genetics and susceptibility to eventually developing deadly asbestos illnesses such as mesothelioma.

The study, which was recently published online in Nature Genetics, found evidence that people with BAP1 gene mutations may have an increased chance of developing multiple cancer types such as mesothelioma, breast, ovarian, pancreatic and renal cancers. The study highlighted two U.S. families with members who have the BAP1 gene mutation. Both families also have “a high incidence of mesothelioma.”

Dr. Joseph R. Testa, another study co-leader and the Carol and Kenneth E. Weg chairman in Human Genetics at Fox Chase Cancer Center, said the study was the first to “demonstrate that individual genetic makeup can greatly influence susceptibility to mesothelioma.”

While only a first step, the discoveries noted in this study could one day lead to fundamental progress in mesothelioma care. Thanks to Drs. Carbone and Testa and their crew for the hard work. We hope this is just the beginning of bigger breakthroughs to come.

Living with the day-to-day hardships of mesothelioma – whether it is you or a loved one who has been diagnosed with the illness – is both emotionally and financially taxing. If you feel that a company or former employer may be responsible for the asbestos exposure that led to an illness, contact a mesothelioma attorney to learn about filing amesothelioma lawsuit.

Mesothelioma